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I Summary  
Basal cell carcinoma (BCC) belongs to the group of non-melanoma skin 
cancers and is the most commonly diagnosed cancer in fair-skinned 
individuals. In the majority of BCC the tumor suppressor gene patched1 
(PTCH) is mutated resulting in aberrant hedgehog (HH) signaling. Analysis of 
human and murine BCC shows that the putative tumor suppressor Wnt 
inhibitory factor 1 (Wif1) is highly expressed by this tumor entity. However, 
malignant forms of skin cancer, i.e. squamous cell carcinomas and 
melanomas, also express Wif1. Thus, the objective of this thesis was to 
analyze the role of Wif1 in BCC by Wif1 overexpression in the BCC cell line 
ASZ001 and by Wif1 depletion in the BCC mouse model 
Ptchflox/floxCreERT2T/-. 
Indeed, tumor-intrinsic Wif1 overexpression in ASZ001 significantly inhibits 
tumor growth in nude mice. The Wif1-mediated tumor suppression was not 
due to diminished vascularization or alterations in canonical Wnt, Hh or 
PI3K/Akt signaling activity. It also was not due to induction of differentiation 
or apoptosis. However, we found that Wif1-expressing tumors were 
characterized by a decrease in Ki67 positive cells which was accompanied 
by phosphorylation of PKC and Erk1 along with moderately increased 
deposition of collagens. Vice versa, BCC growth is enhanced in 
Ptch-knockout mice on a Wif1-deficient background due to an increase in 
proliferation. Together, the data suggest that Wif1 is both necessary and 
sufficient to restrict BCC growth and may be one of the factors that are 
responsible for the very low metastatic potential of this tumor entity. 
 




II.1 Basal cell carcinoma (BCC) 
BCC belongs to the group of non-melanoma skin cancers and is the most 
commonly diagnosed cancer in fair-skinned individuals. As it is not reported 
to cancer registries, the precise incidence of BCC is unknown. However, it is 
estimated that BCC account for nearly half of all cancers in the United States 
of America (USA). In Europe, the incidence of BCC ranges from 44.6 to 128 
per 100,000 inhabitants (Rubin et al. 2005; Trakatelli et al. 2007)(American 
Cancer Society 2015). The average lifetime risk for fair-skinned individuals to 
develop a BCC is approximately 30 % (Abdulla et al. 2005). Thus, BCC is the 
most common tumor in humans. 
In contrast to other skin tumors such as squamous cell carcinoma (SCC) and 
melanoma, BCC are semi-malignant tumors. They have a good overall 
prognosis, with a high chance of cure when diagnosed early (Robinson and 
Dahiya 2003). This is due to the fact that BCC have a low metastatic 
potential as metastasis occurs in only 0.0028-0.55 % of all patients 
(Soleymani et al. 2008). In addition, approximately 20 % of BCC show signs 
of spontaneous regression (Curson and Weedon 1979). However, BCC can 
cause substantial morbidity due to its multiplicity, local recurrence and tissue 
invasion and destruction (Basset-Seguin et al. 2015).  
The clinical presentation of BCC is diverse. Consequently, BCC can be 
classified histopathologically as indolent-growth or aggressive-growth 
subsets. The indolent-growth variants comprise superficial and nodular BCC 
subtypes with nodular BCC being the most common BCC subtype (Crowson 
2006). Aggressive-growth tumors include infiltrative BCC, metatypical BCC 
and morpheaform or sclerosing BCC.  
BCC can also be classified according to their differentiation status. This 
includes keratotic, infundibulocystic, follicular, pleomorphic BCC, BCC with 
eccrine differentiation, BCC with sebaceous differentiation, the 
fibroepithelioma of Pinkus and BCC with myoepithelial differentiation 
(Crowson 2006). 
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BCC most frequently occur at sun-exposed sites of the skin (Nakayama et al. 
2011) and several epidemiologic studies indicate that exposure to sun light is 
the main risk factor for BCC formation. Other risk factors comprise fair skin, 
age, immune suppression and exposure to arsenic (Boonchai et al. 2000; 
Dessinioti et al. 2010).  
Although the vast majority of BCC occur sporadically, a rare heritable 
disorder exists, that predisposes patients to the development of multiple BCC 
during their lifetime. This syndrome is known as basal-cell nevus syndrome 
(BCNS), or Gorlin-Goltz syndrome or nevoid basal-cell carcinoma syndrome. 
By genetic linkage analysis of relatives with BCNS, the mutation bearing 
locus was mapped to human chromosome 9q22 and then to the patched 1 
(PTCH) gene (Hahn et al. 1996; Johnson et al. 1996). Indeed, mutations of 
PTCH are responsible for BCC development in BCNS patients. Upon this 
discovery, PTCH was shown to be mutated in about 90 % of all spontaneous 
BCC. Other BCC associated mutations are activating mutations in 
smoothened (SMO) (Lam et al. 1999), mutations in suppressor of fused 
homolog (SUFU) and in tumor protein p53 (TP53) (Reifenberger et al. 2005). 
BCC also develop in Ptch mutant mice comprising the Ptchneo67/+ (Mancuso 
et al. 2004) and the Ptchflox/flox  (Zibat et al. 2009; Nitzki et al. 2010) mouse 
models, in a mouse model expressing a constitutively active Smo mutant 
(SmoM2) (Xie et al. 1998) and in a mouse model overexpressing sonic 
hedgehog (Shh) (Oro et al. 1997). These mouse models are valuable tools to 
investigate the molecular mechanisms of BCC pathogenesis.  
The cellular origin of BCC is still debated. However, analysis of Ptch 
knockout or transgenic SmoM2 mouse models revealed that BCC can 
originate from progenitor cells of the interfollicular epidermis and the upper 
infundibulum of the hair shaft (Youssef et al. 2010) and from hair follicle stem 
cells (Nitzki et al. 2010; Peterson et al. 2015) caused by aberrantly activated 
Hedgehog (Hh) signaling. 
BCC treatment comprises surgical or non-surgical techniques depending on 
several tumor- and patient-related factors. The best results are achieved 
upon surgery including Mohs micrographic surgery, La Galette technique, 
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conventional surgery with tumor-adapted margins of safety, curettage, 
electrodesiccation, and cryosurgery (Goppner and Leverkus 2011). 
Non-surgical treatment options comprise radiotherapy, photodynamic 
therapy, and topical application of imiquimod and 5-fluorouracil. For 
advanced or metastatic BCC the Food and Drug Administration (FDA) 
approved the Smo inhibitor vismodegib (trade name Erivedge®) that can be 
either applied systemically or topically (Basset-Seguin et al. 2015). In 
particular, patients with multiple comorbidities and inoperable tumors benefit 
from these non-surgical techniques. However, compared to surgery non-
surgical treatments can result in increased recurrence rates.  
Due to its high and rising incidence and its increasing occurrence in young 
people BCC are becoming more and more problematic for the health care 
system. Non-melanoma skin cancer (i.e. BCC and SCC) account for 9% of 
the total costs of all cancers in 2000-2001 in Australia (Staples et al. 2006). 
Better therapeutic approaches may help to reduce these costs. This, 
however, necessitates a better knowledge about molecular events in BCC 
growth, progression or regression. Particularly factors and mechanisms that 
keep BCC a slowly growing tumor entity could enable us to employ these 
findings as prospective treatment options.  
 
 
II.2  Signaling pathways in BCC 
Multiple pathways are known to be misregulated in BCC. Among these are 
the Hh and Wnt signaling pathway (see below). Moreover, components of 
pathways regulating cell cycle progression and controlling apoptosis are 
frequently found to be mutated  (TP53) or misregulated (platelet derived 
growth factor receptor-α (PDGFRα) and B cell leukemia/lymphoma 2 (BCL2)) 
in BCC (Xie et al. 2001; Vidal et al. 2004; Reifenberger et al. 2005).  
Furthermore, epidermal growth factor receptor (EGFR) signaling plays an 
important role in BCC. Receptors of this pathway, ErbB1, 2 and 3 were 
shown to be expressed in BCC (Krahn et al. 2001; Schnidar et al. 2009) and 
epidermal-specific deletion or irreversible inhibition of EGFR inhibits BCC 
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growth (Eberl et al. 2012). Downstream of activated EGFR several signaling 
cascades including mitogen-activated protein kinase (MAPK) and  
phosphatidylinositol-4,5-bisphosphate 3-kinase/v-akt murine thymoma viral 
oncogene homolog (PI3K/Akt) signaling have been reported to be involved in 
BCC growth (Schnidar et al. 2009; Hafner et al. 2010). In particular, the 
inhibition of the Mapk kinase 1/2 (Mek1/2) was shown to suppress the 
proliferation of the BCC cell line ASZ001 (Xie et al. 2001).  
As EGFR signaling is also relevant in this thesis a more detailed summary of 
this pathway is given. EGFR signaling is involved in the regulation of a 
variety of cellular responses including  proliferation, differentiation, migration 
and apoptosis (Yarden and Sliwkowski 2001; Chong and Janne 2013) and 
has a crucial role in the initiation and maintenance of several solid tumors 
(Arteaga and Engelman 2014).  In the extracellular space ligands containing 
epidermal growth factor (EGF)-like domains can bind to the v-erb-b2 
erythroblastic leukemia viral oncogene homolog (ErbB) receptors (Yarden 
and Sliwkowski 2001). ErbB family members are receptor tyrosine kinases 
(RYKs) and comprise the epidermal growth factor receptor ErbB1 (EGFR, 
also HER1), ErbB2 (also HER2 or Neu), ErbB3, and ErbB4 (Yarden and 
Sliwkowski 2001). Upon binding of EGF-like growth factors to the 
extracellular domain, the ErbB receptors form homo- and heterodimers 
resulting in auto- or transphosphorylation of the cytoplasmic domains. The 
phosphorylated domains serve as binding sites for various proteins involved 
in the regulation of multiple intracellular signaling cascades (Yarden and 
Pines 2012). Which signaling cascade is activated depends on the respective 
receptor dimers, as all ErbB family members have distinct biochemical 
properties and interaction partners (see Fig. 1) (Nyati et al. 2006; Yarden and 
Pines 2012).  
First, EGFR phosphorylation can induce the activation of signal transducer 
and activator of transcription (STAT) by Janus kinase (JAK). Activated STAT 
in turn translocates into the nucleus and directly regulates gene expression 
crucial for cell survival, proliferation, transformation and oncogenesis 
(Bowman et al. 2000). 
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Second, EGFR activates PI3K that phosphorylates PIP2 to form 
phosphatidylinositol-3,4,5-triphosphate (PIP3), which then activates Akt by 
phosphorylation. Phosphorylated Akt has several effects, both in the 
cytoplasm and in the nucleus, which include the inhibition of proapoptotic 
factors such as BAD (BCL2 antagonist of cell death), pro-caspase 9 and the 
Forkhead (FKHR) family of transcription factors (FOXO). Moreover, Akt-
mediated activation of mammalian target of rapamycin (mTOR) is involved in 
the regulation of cell proliferation by controlling the activity of ribosomal 
protein S6 (S6) (Wendel et al. 2004; Ruvinsky and Meyuhas 2006; 
Hemmings and Restuccia 2015). 
Third, activation of small GTPase rat sarcoma virus oncogene homolog (Ras) 
by phosphorylation is mediated by son of sevenless (SOS) triggering a 
MAPK signaling cascade. Activated Ras binds to Raf (MAP3K), which in turn 
triggers the phosphorylation of MEK1/2 and MAPK3/1 (also named 
extracellular signal-regulated kinases (ERK) 1/2 or p44/p42). Phosphorylated 
ERK1/2 translocates into the nucleus and activates various transcription 
factors such as ELK1 (McCubrey et al. 2012). 
Fourth, PLC binds to phosphorylated EGFR inducing its activity. 
Subsequently, PLC hydrolyses phosphatidylinositol-4,5-bisphosphate (PIP2) 
to 1,2 diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). DAG 
mediates the activation of protein kinase C (PKC) regulating cell-cycle 
progression, transformation, differentiation and apoptosis (Oliva et al. 2005). 




Fig. 1: EGFR signaling pathway 
The shown signaling cascade does not include all the known components of a given pathway, and cross-talks are 
not shown for clarity. Activated EGFR signaling can result in the induction of different pathways leading to the 
activation of ERK, STAT, Akt, S6 and/or PKC. Modified from: (Nyati et al. 2006). 
 
 
II.3  Hh signaling 
The Hh signaling pathway is highly conserved between the species and its 
signaling is required for tissue homeostasis and regeneration (Beachy et al. 
2004). In brief, Hh is a morphogen and three mammalian homologues of the 
Drosophila segment polarity gene hedgehog exist. These are sonic (Shh), 
indian (Ihh) and desert (Dhh) hedgehog, all of which are all secreted proteins. 
Shh is the most broadly expressed Hh homologue. In vertebrate 
development Shh is mainly required for polarization and pattern formation of 
the limb bud and of the neural tube. Ihh regulates bone and cartilage 
development and Dhh is essential for germ cell development in the testis and 
peripheral nerve sheath formation (Petrova and Joyner 2014). Hh signaling 
requires the autoproteolytic cleavage of the Hh precursor into an N-terminal 
(Hh-N) and a C-terminal (Hh-C) moiety. After several post-translational 
modifications including an addition of a cholesterol moiety at the C-terminus 
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and palmitoylation at the N-terminus of Hh-N, it is secreted by means of the 
membrane transporter protein dispatched (Disp) (Burke et al. 1999; Ma et al. 
2002; Beachy et al. 2010).  
In the extra cellular space the distribution of Hh is dependent on heparan 
sulfate proteoglycans (HSPGs) (Chang et al. 2011), where it can bind to the 
two extracellular loops of the 12-pass transmembrane receptor Ptch (Briscoe 
et al. 2001). The association of Hh to Ptch is increased by the 
transmembrane proteins cysteine dioxygenase 1, cytosolic (Cdo1) and 
biregional cell adhesion molecule-related/down-regulated by oncogenes 
(Cdon) binding protein (Boc) (Yao et al. 2006). Ptch is a negative regulator of 
the Hh signaling pathway (Epstein 2008); (Pasca di Magliano and Hebrok 
2003). In the absence of Hh ligand, Ptch inhibits the activation of the G-
protein coupled receptor Smo, in turn keeping glioma-associated oncogene 
family member (Gli) transcription factors inactive in the cytoplasm. When Hh 
is present, Ptch becomes internalized into the cell, resulting in suspension of 
Smo inhibition. Subsequently, Smo facilitates the translocation of the 
activator forms of Gli transcription factors into the nucleus where they induce 
the expression of Hh target genes (see Fig. 2) by binding to the conserved 
Gli binding site 5’-GACCACCCA-3’ (Hallikas et al. 2006). The Gli protein 
family consists of 3 distinct proteins (Gli1, 2 and 3). Gli2 and Gli3 are 
bifunctional transcription factors facilitating either transcriptional repression or 
activation. When Hh signaling is inactive Gli2 and Gli3 are phosphorylated 
and subsequently proteolytically cleaved to generate the repressor forms 
(Gli2R and Gli3R, respectively). When Hh is present, the activation of Smo 
results in the transport of uncleaved, activated Gli2 and Gli3 proteins from the 
cilia to the nucleus. Gli1, which is a downstream target gene of active Hh 
signaling but not immediately involved in signal transduction, is a strong 
potentiator of the signaling cascade (Roberg-Larsen et al. 2014). 
When Ptch is mutated, the resulting protein is incapable of inhibiting Smo. 
This results in pathological, constitutive active Hh signaling, ultimately 
leading to cancer formation such as BCC in both humans and mice (see Fig. 
2) (Athar et al. 2006).  
 






   
Fig. 2: Pathologically activated Hh signaling pathw ay 
Left panel: inactive pathway, Ptch inhibits Smo and Gli transcription factors remain inactive in cytoplasm; middle 
panel: Hh binds to its receptor Ptch leading to a translocation of Gli transcription factors into the nucleus; right panel: 




II.4 Wnt signaling  
The wingless-type MMTV integration site family member (Wnt) signaling is a 
central pathway in development, tissue regeneration and homeostasis. Wnts 
are secreted proteins that act as morphogens in the extracellular space. For 
secretion they require the activity of the palmitoyltransferase porcupine 
(Porcn) adding a palmitate modification to the premature Wnt proteins. This 
lipid modification leads to the binding of the 7-transmembrane protein wntless 
(Wls) conveying Wnt to the plasma membrane for secretion (Banziger et al. 
2006). At the target cell Wnt ligands can induce the activity of β-catenin-
dependent Wnt signaling (canonical) or β-catenin-independent (non-
canonical) signaling. The non-canonical signaling comprises at least the 
Wnt/planar cell polarity (PCP) and Wnt/Ca2+ signaling. 
In the extracellular space Wnt signaling can be blocked at the receptor level 
by dickkopf (Dkk) binding to the single-span transmembrane receptor LDL 
receptor-related protein 5/6 (Lrp5/6) or by direct binding and sequestration of 
Wnts either by the secreted frizzled-related protein (Sfrp) or by 
Wnt inhibitory factor 1 (Wif1) (Malinauskas and Jones 2014).  
  inactive                    physiologically                 pathologically  
                                       activated                            activated 
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When  canonical Wnt signaling is inactive, β-catenin is continuously 
phosphorylated by the serine/threonine kinases glycogen synthase kinase 3 
(Gsk3) and casein kinase 1 (Ck1) as part of the destruction complex 
(composed of Gsk3, Ck1, dishevelled (Dvl), Axin1, adenomatosis polyposis 
coli (Apc) and beta-transducin repeat containing protein (β-TrCP)) (see Fig. 
3). Phosphorylated β-catenin is subsequently ubiquitinated by β-TrCP, a 
component of the E3 ubiquitin ligase complex, and degraded by the 
proteasome (Clevers and Nusse 2012). The absence of β-catenin allows the 
T-cell factor/lymphoid enhancer factor (Tcf/Lef) transcription factors, in 
particular Tcf3 and Tcf4 (Liu et al. 2005), to interact with transducin-like 
enhancer of split, homolog of Drosophila E (spl) (Tle, or groucho). The 
binding of Tle prevents Wnt target gene transcription (Cadigan and 
Waterman 2012).  When canonical Wnt signaling is active, Wnt ligands bind 
with the palmitate group to the cysteine-rich domain of their receptor cognate 
frizzled (Fzd) receptor. Moreover, Wnt ligands bind the Lrp5/6 co-receptor, 
inducing it to form a complex with Fzd. This results in a conformational 
change of the receptors inducing the phosphorylation of Lrp5/6. This recruits 
Axin1 as part of the intact destruction complex leading to the dissociation of 
β-TrCP. Thus, phosphorylated β-catenin is no longer ubiquitinated and 
consequently not degraded. This leads to a saturation with phosphorylated 
β-catenin at the destruction complex and inhibition of the latter (Li et al. 
2012). Only β-catenin that is newly synthesized after initiation of the Wnt 
signal is signaling competent (Staal et al. 2002). In its active stage β-catenin 
remains unphosphorylated and accumulates in the cytoplasm resulting in its 
translocation into the nucleus. In the nucleus active β-catenin can bind to 
Tcf/Lef transcription factors, in particular Tcf1 and Lef1 (Behrens et al. 1996; 
Molenaar et al. 1996; Liu et al. 2005). Tcf/Lef transcription factors can directly 
bind to DNA bearing the motif 5`-CCTTTGATCTT-3` (van de Wetering et al. 
1997) which is also employed in the TOP/FOP reporter system (Korinek et al. 
1997). When β-catenin binds Tcf/Lef transcriptional activators in a complex 
containing CREB-binding protein (Cbp), B cell CLL/lymphoma 9 (Bcl9) and 
pygopus (Pygo) it drives Wnt target genes expression in a tissue- and 
developmental stage-specific manner. Axin2 is considered as a general 
transcriptional target gene of active Wnt/β-catenin signaling and thus serves 
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an indicator of an active signaling pathway (Lustig et al. 2002). In contrast to 
the proposed model of an intact destruction complex and the dissociation of 
β-TrCP described above, it is also discussed that the destruction complex is 
resolved into its compounds as a result of recruitment of Axin to the Fzd 
receptor. Which model turns out to hold true is an ongoing debate. 
 
        
    
Fig. 3: canonical Wnt signaling pathway 
Left panel: inactive pathway; proteasome cleaves ubiquitinated β-catenin preventing target gene expression. Right 
panel: active pathway; Conformational change of the activated receptors result in the dissociation of βTrCP 
abrogating ubiquitination of β-catenin and thus proteasomal degradation; newly synthesized β-catenin accumulates 
and translocates into the nucleus triggering target gene expression. Modified from: (Clevers and Nusse 2012). 
 
In contrast to canonical Wnt signaling, the Wnt/PCP pathway is independent 
from β-catenin. It controls the cell shape, directional migration, asymmetric 
cell division, and cellular orientation which is required for normal 
development and function of complex tissues (Kaucka et al. 2015). Wnt/PCP 
signaling is activated by the binding of Wnts to Fzd receptor and the co-
receptors receptor tyrosine kinase-like orphan receptor 1 and 2 (Ror1/2), the 
Ryk, or the protein tyrosine kinase 7 (Ptk7) (Green et al. 2014). At the cell 
surface PCP signaling can be blocked by vang-like (Vangl, or strabismus). 
The cytoplasmic tail of Vangl binds and recruits prickle (Pk) to the plasma 
membrane, where Prickle binds and thereby antagonizes the recruitment of 
Dvl to Fzd resulting in an inhibition of Wnt/PCP signaling (Wang 2009). 
Activation of the pathway by Wnt ligands results in the recruitment of 
  inactive                                            activated                                          
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cytoplasmic Dvl to the Fzd receptor. When the pathway is active, ankyrin 
repeat domain (Ankrd, or diego) binds to Dvl and prevents Pk from binding 
and inhibiting Dvl (Devenport 2014). At the level of Dvl, two parallel pathways 
result in the activation of the GTPases Rho and Rac (Habas et al. 2003). The 
first activates dishevelled associated activator of morphogenesis 1 (Daam1) 
resulting in the activation of the Rho-associated coiled-coil containing protein 
kinase (Rock) inducing cytoskeletal reorganization (Kim and Han 2005). 
Furthermore, Daam1 is a formin-homology protein and a direct nucleator of 
linear actin filaments (Watanabe and Higashida 2004). The second pathway 
activates Rac, which in turn stimulates Mapk8 (JNK) activity modulating actin 
cytoskeleton (Habas et al. 2003).  
The second β-catenin independent Wnt pathway is Wnt/Ca2+ signaling (see 
Fig. 4).  This pathway is activated upon binding of specific Wnt ligands to Fzd 
receptor leading to the activation of phospholipase C (PLC).  Activated PLC 
cleaves membrane bound phospholipid PIP2 in IP3 and DAG. IP3 triggers 
Ca2+ influx from the endoplasmic reticulum (ER), which activates several 
effector proteins including calcium/calmodulin-dependent protein kinase II 
(CaMKII), PKC and calcineurin (Cn). These kinases regulate and activate a 
multitude of target proteins including nuclear factor of kappa light polypeptide 
gene enhancer in B cells (Nf-κB), cAMP responsive element binding protein 
(Creb), Erk and nuclear factor associated with T cells (Nfat) (Sheldahl et al. 
1999; Kuhl et al. 2000; Hogan et al. 2003) that in turn drive the expression 
various target genes regulating cell survival and proliferation. 




Fig. 4: Wnt/Ca 2+signaling pathway 
Wnt binding to the receptor Fzd triggers the activation of PLC. This leads to the cleavage of PIP2 in DAG and IP3. 
IP3 induces an efflux of Ca
2+ from the endoplasmic reticulum (ER) into the cytoplasm. Elevated cytoplasmic Ca2+ 
levels and DAG induce the activation of CaMKII, Cn and PKC triggering target gene expression by various effector 
proteins. Modified from: (Lories et al. 2013). 
 
Although the canonical and non-canonical pathways are here separately 
described, they influence and inhibit each other at various interfaces 
(Weidinger and Moon 2003). In the past, Wnts and their cognate receptors 
were also classified as either canonical or non-canonical. However, each of 
the 19 Wnts can bind to several Fzd receptors and each of the 10 Fzd 
receptors can bind several Wnts, making Wnt signaling highly context 
specific (van Amerongen and Nusse 2009). 
 
 
II.5 Wnt signaling in BCC 
Beside Hh signaling Wnt signaling has been shown to be involved in BCC 
tumorigenesis (Doglioni et al. 2003; El-Bahrawy et al. 2003). In the SmoM2 
BCC mouse model constitutive Hh signaling induces canonical Wnt target 
gene expression in tumor cells and in surrounding stromal cells. In the same 
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context, inhibition of canonical Wnt signaling via Dkk1 results in suppression 
of tumor formation (Yang et al. 2008). Consistently, human BCC samples 
also exhibit nuclear accumulation of β-catenin and thus active canonical Wnt 
signaling (Salto-Tellez et al. 2006).  
Moreover, it has been speculated that canonical Wnt signaling enhances 
BCC development by modulation of the Hh pathway activity (Yang et al. 
2008). Indeed, Wnt signaling was shown to alter Hh signaling and vice versa.  
For example Gli3R is capable of inhibiting canonical Wnt signaling by 
antagonizing β-catenin (Ulloa et al. 2007). Interestingly, the generation of 
Gli3R is triggered by sequential phosphorylation involving Gsk3 which is also 
part of the destruction complex in canonical Wnt signaling facilitating 
β-catenin phosphorylation to mark it for proteasomal degradation (see 
section I.3) (Hui and Angers 2011). Furthermore, Sufu has been shown to 
bind to β-catenin leading to its nuclear export and to the inhibition of target 
gene expression. Mutated Sufu lacking this property leads to both active Hh 
and Wnt signaling (Taylor et al. 2004).  
In development both Wnt and Hh signaling need to be tightly coordinated to 
determine the cell fate decision in various organs (Li et al. 2009). Thus, it is 
very likely that Wnt and Hh signaling also influence each other in BCC. 
Indeed, canonical Wnt signaling induces expression of GLI1 via insulin-like 
growth factor 2 mRNA binding protein 1 (Igf2bp1). When downregulated, 
Igf2bp1 suppresses the growth of BCC (Noubissi et al. 2014). Furthermore, 
the expression of constitutively active β-catenin in the absence of vitamin D 
receptor leads to the formation of BCC-like lesions with up-regulated Ptch 
expression (Palmer et al. 2008).  
In contrast, activation of Wnt/Ca2+ signaling by tumor stroma derived Wnt5a 
induces the differentiation and regression of BCC in a CaMKII-dependent 
manner (Nitzki et al. 2010).  
In conclusion, these studies reflect the significant function of Wnt signaling in 
BCC development (Lim and Nusse 2013). 
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II.6 Wif1  
Wif1 was first identified as an expressed sequence tag from human retina. 
The initial hint that Wif1 affects Wnt signaling was derived from experiments 
with early Xenopus embryos when injection of RNA encoding for human 
WIF1 caused a partial axis duplication and abnormal somitogenesis which 
both were known to be controlled by the Wnt signaling pathway (Hsieh et al. 
1999). Wif1 is highly conserved in human, mouse, Xenopus and zebrafish 
and consists of an N-terminal signal sequence for secretion, five EGF-like 
repeats, a hydrophilic C-terminus and a WIF domain (WD) which is also 
present in the Wnt receptors Ryk/Derailed (Drl) (Patthy 2000; Yoshikawa et 
al. 2003) (see Fig. 10).  
In the mouse the Wif1 gene is located on chromosome 10 and in humans on 
chromosome 12. It encodes for transcripts of 2294 or 2238 bp in length, 
respectively. For both mouse and human the transcript comprises 10 exons 
with a protein coding sequence of 1140 bp length which is translated into a 
~42 kDa protein consisting of 379 amino acids (according to NCBI CCDS 
database).  
Human WIF1 directly binds eight Wnts (3a, 4, 5a, 7a, 9a, 11 (Surmann-
Schmitt et al. 2009)), to the Drosophila orthologue of Wnt, wingless, and to 
Xenopus Wnt8 (Hsieh et al. 1999)) by its WD and at least partially by its 
EGF-like domains (Malinauskas et al. 2011). Moreover, the EGF-like 
domains contain a HSPG-binding site suggesting that Wif1 facilitates the 
interaction between Wnts and HSPG in the extra cellular space. Other 
studies showed that the Drosophila Wif1 homolog shifted also facilitates 
interactions of Hh and HSPGs and thereby fosters Hh signaling (Glise et al. 
2005; Gorfinkiel et al. 2005). More recently it was revealed that zebrafish 
Wif1 affects Hh signaling in Drosophila, likewise suggesting a possible role 
for Wif1 as a modulator of vertebrate Hh signaling (Avanesov et al. 2012).  
In summary, Wif1 possibly modulates both Wnt and Hh signaling which are 
dysregulated in a variety of malignancies including BCC.  
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Wif1 itself also plays a role in tumor development as it suppresses growth of 
many different tumors. In contrast, also an oncogenic role of Wif1 has been 
suggested (Huang et al. 2014). Thus, Wif1 is upregulated in some 
adenocarcinoma cell lines and intestinal adenomas of Apc min/+ mice (Cebrat 
et al. 2004). However, Wif1 upregulation could be regarded as a negative 
feedback loop and therefore a side effect of the constitutive activity of 
canonical Wnt signaling without any significance for the growth of adenomas. 
This is due to the fact that Apc mutant cells are insensitive towards 
extracellular Wnt inhibitors with respect to the downregulation of β-catenin 
driven target gene expression.  
As already mentioned, most published data show that reduced levels of Wif1 
expression is associated with enhanced tumor growth, whereas Wif1 
overexpression is connected with tumor growth inhibition. Thus, disruption of 
the murine Wif1 gene results in the development of radiation-induced 
osteosarcomas (Kansara et al. 2009). Promoter methylation induced 
downregulation of WIF1 expression is present in numerous human cancers 
(Mazieres et al. 2004; Haqq et al. 2005; Taniguchi et al. 2005), whereas 
overexpression of WIF1 inhibits the growth of lung, bladder cancer and 
melanoma cells (Kim et al. 2007; Lin et al. 2007; Tang et al. 2009). Recently, 
a rare missense mutation of Wif1 in combination with a mutation in 
heterogeneous nuclear ribonucleoprotein A0 (HNRNPA0) has been shown to 
predispose members of a large family to multiple cancers (Wei et al. 2015).  
These data demonstrate that Wif1 plays a tumor suppressive role in a variety 
of tumor entities.  
Previous experiments of our group showed that Wif1 is highly upregulated in 
BCC derived from Ptchflox/floxCreERT2T/- mice (König 2012). The same 
applies to BCC of the SmoM2 mouse model (Youssef et al. 2012). This 
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II.7 Objectives  
The aim of this thesis was to analyze the role of Wif1 in BCC. For this 
purpose, three experimental approaches were pursued. 
First, I investigated the Wif1 expression levels in laser microdissected human 
BCC and compared it with human SCC and melanomas and correlated the 
expression levels with the degree of malignancy of the respective tumor 
entity. 
Second, I analyzed the function of Wif1 in the BCC cell line ASZ001, which is 
derived from irradiated Ptch+/- mice. Since ASZ001 express low levels of 
Wif1, I have introduced Wif1 by retroviral transduction. This allowed for 
analyzing the effects of Wif1 on BCC cell growth in vitro. The analyses 
comprised Wif1 related effects on apoptosis, cell viability, proliferation, cell 
cycle progression, differentiation, migratory capacity and on Wnt, Hh and 
EGFR pathway activity. Moreover, I transplanted control and Wif1 
overexpressing ASZ001 (hereafter ASZ-pMSCV and ASZ-Wif1, respectively) 
subcutaneously in nude mice to study the effect of Wif1 on tumor growth in 
vivo. After excision the tumors were subjected to the same analyses as 
mentioned above. In addition, vascularization, EMT and stromal composition 
of the tumors were investigated. 
Third, Ptchflox/floxCreERT2T/- mice (in which BCC can be conditionally induced 
by injection of tamoxifen) were crossed onto a Wif1-deficient background. 
After BCC induction in the resulting offspring the tumors were analyzed after 
45 and 90 days with respect to size and proliferative capacity. 
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III Material and methods 
III.1  Software 
Table 1: Software 
Software  Supplier  
4D v13 Volume Desktop Version 13.4   4D SAS, Clichy-la-Garenne, France 
ABI 3500 XL Data Collection Software v3.0 Applied Biosystems, Darmstadt 
BD FACSDiva Becton Dickinson GmbH, Heidelberg 
BioEdit 7.0.9 Ibis Biosciences, Carlsbad, USA 
Endnote X5  Thomson ISI Research Soft , California, USA 
cellSens Dimension Olympus, Shinjuku, Japan 
CeligoS S software 2.01 Cyntellect, San Diego, USA 
Chromas Lite 2.01 Technelysium Pty Ltd, Helensvale, Australia 
Fiji (Schindelin et al. 2012) 
FlowJo  Tree Star Inc., Oregon, USA 
FluorChemQ SA Version 3.2.2.0 Cell Biosciences Inc., Heidelberg 
FreeHand MX Adobe Systems Incorporated, San Jose, USA 
Gen5 1.11  BioTek Instruments, Inc., Bad Friedrichshall 
GraphPad Prism 6 GraphPad Software, La Jolla, USA 
Intas GDS Intas Science Imaging Instruments GmbH, Göttingen 
Microsoft Office 2007 Microsoft Co., Redmont, USA 
MMI CellTools 4.0 Molecular Machines & Industries GmbH, Eching 
Photoshop 6.0 Adobe Systems Incorporated, San Jose, USA 
SDS 2.2. Applied Biosystems, Darmstadt 
Sequencing Analysis Software v5.4 Applied Biosystems, Darmstadt 
 
 
III.2 Databases and web pages 
Table 2: Databases and web pages 
Database or webpage  Uniform Resource Locator  
BLAST http://blast.ncbi.nlm.nih.gov/Blast.cgi 
Expression Atlas http://www.ebi.ac.uk/gxa/home 
HUGO Gene Nomenclature http://www.genenames.org/ 
MGI_3.54-Mouse Genome Informatics http://www.informatics.jax.org/ 
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National Center for Biotechnology Information 
(NCBI) 
http://www.ncni.nlm.nih.gov/ 
Oligo Analyzer http://eu.idtdna.com/calc/analyzer 
RT Primer DB http://medgen.ugent.be/rtprimerdb/index.php 
The Human Protein Atlas http://www.proteinatlas.org 




Table 3: Equipment 
Equipment  Supplier  
-80°C Freezer (MDF-U71V) Sanyo Electric  Co. Ltd., Moriguchi, Japan 
Accu-jet Brand GmbH & Co. KG, Wertheim,  
Agarose gel electrophoresis chamber Peqlab Biotechnology GmbH, Erlangen 
Arium® 611 VF water purification system Sartorius, Göttingen 
Autoclave (sanoclav) W. Krannich GmbH & Co. KG, Göttingen 
Biophotometer (6131) Eppendorf AG, Hamburg 
Bunsen burner (Gasprofi 2 scs) WLD-TEC GmbH, Göttingen 
(CO2-) Incubator (6000, BBD 6220) Kendro Laboratory Products GmbH, Hanau 
Cold light source (KL 200) Schott Glas, Mainz 
Cytometer Celigo S Cyntellect, San Diego, USA 
Digital Monochrome Printer P91D Mitsubishi, Ratingen 
Digital Photocamera (PowerShot G2) Canon Deutschland GmbH, Krefeld 
Exposure cassettes Sigma-Aldrich Chemistry GmbH, Steinheim 
FACS Calibur  BD Biosciences GmbH, Heidelberg 
FluorChemQ Detection System Cell Biosciences Inc., Heidelberg 
Freezer (-20°C) Liebherr GmbH, Ochshausen 
Fridge (4°C) Robert Bosch GmbH, Stuttgart 
Heating block (Thermomixer) Eppendorf AG, Hamburg 
Heating stirrer (MR 3000/3001) Heidolph Instruments, Schwabach 
High-precision scales (Sartorius Basic plus) Sartorius AG, Göttingen 
Homogenizer (Miccra D-1) ART Prozess- & Labortechnik GmbH & Co. KG, Müllheim 
Hybridization oven (HB-1000 Hybridizer) UVP Inc., Upland, USA 
Inverse microscope with fluorescence filter 
(Axiovert 25, FilterSet 43, 01, 09) 
Carl Zeiss Jena GmbH, Jena 
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Liquid nitrogen tank  L’air liquid S.A., Paris, France 
LSR II BD Biosciences GmbH, Heidelberg 
Luminometer (Synergy Mx) BioTek Instruments, Inc., Bad Friedrichshall 
Mastercycler ep gradient S Eppendorf AG, Hamburg 
Mercury-short-arc lamp(HBO 50W/AC) OSRAM AG, Munich 
Microtome (HN 40) New Brunswick Scientific GmbH, Nürtingen, 
Mini centrifuge Carl Roth GmbH & Co. KG, Karlsruhe 
MMI CellCut Molecular Machines & Industries GmbH, Eching 
Mr. FrostyTM Freezing Container Thermo Fisher Scientific GmbH, Schwerte 
Multipette Eppendorf AG, Hamburg 
One-channel pipettes Eppendorf AG, Hamburg 
Paraffin dispenser (Dispenser PAG 12) MEDITE GmbH, Burgdorf 
PCR machine (Primus HT) MWG AG Biotech, Ebersberg 
pH-meter (inoLab pH Level 1) WTW GmbH, Vienna, Austria 
Power supply for electrophoresis Peqlab Biotechnology GmbH, Erlangen 
shaking incubator New Brunswick Scientific GmbH, Nürtingen 
shaking waterbath (1083) GFL GmbH, Burgwedel 
Sequencer (ABI 3500 XL) Thermo Fisher Scientific Inc., Waltham, USA 
Stereo microscope (Stemi 2000) Carl Zeiss Jena GmbH, Jena 
Sterile bench (Euroflow class IIA) Clean Air Techniek bv, Woerden, Netherlands 
TaqMan (ABI Prism 7900HT) Thermo Fisher Scientific Inc., Waltham, USA 
Thermoprinter (DPU-414) Eppendorf AG, Hamburg 
Tissue embedding and rehydrating machine  
(TP 1020) 
Leica Microsystems GmbH, Bensheim 
Trans-Blot SD semi-dry transfer cell Bio-Rad Laboratories GmbH, München 
UV transilluminator Intas Science Imaging Instruments GmbH, Göttingen 
Vacuum pump Schütt Labortechnik, Göttingen 
Vortexer-Genie 2 Scientific Industries, Inc., Woburn, USA 
Weighing scale (Sartorius Basic plus) Sartorius AG, Göttingen 










Table 4: Consumables 
Consumable  Supplier  
1.5 ml reaction tubes Ochs GmbH, Bovenden/Lenglern 
1.5 ml Safeseal Microtubes  Sarstedt AG & Co., Nürnberg 
13 ml tubes Sarstedt AG & Co., Nürnberg 
15 ml tubes Greiner Bio-One GmbH, Frickenhausen 
2.0 ml reaction tubes Sarstedt AG & Co., Nürnberg 
24-well cell culture plate Corning Inc., Corning, USA 
384-well Optical Reaction Plate Thermo Fisher Scientific Inc., Waltham, U.S.A. 
50 ml tubes Greiner Bio-One GmbH, Frickenhausen 
6-well cell culture plate Corning Inc., Corning, USA 
96-well Assay Plate Corning Inc., Corning, USA 
96-well Optical Reaction Plate Thermo Fisher Scientific Inc., Waltham, USA. 
Balance oeco multi-function paper inapa tecno, Hamburg 
BD DiscarditTM II (2,10,20 ml) BD Biosciences GmbH, Heidelberg 
BD Microfine + Demi BD Biosciences GmbH, Heidelberg 
BD Plastipak BD Biosciences GmbH, Heidelberg 
BD Plastipak 1 ml Sub-Q BD Biosciences GmbH, Heidelberg 
Blotting paper (GB 33 B003) Heinemann Labortechnik GmbH, Duderstadt 
Cell culture dishes, 35 mm, 100 mm, (Nunclon 
Surface) 
Nunc GmbH & Co.KG, Wiesbaden 
Cell culture inserts, 24 well, 8.0 µm Corning Inc., Corning, USA 
Cell culture inserts, 24 well, 0.4 µm Corning Inc., Corning, USA 
Cell scraper Sarstedt AG & Co., Nürnberg 
Combitips plus (0.2, 0.5, 2.5, 5,10 ml) Eppendorf AG, Hamburg 
Coverslips Menzel GmbH & Co.KG, Braunschweig 
Cryo Pure Sarstedt AG & Co., Nürnberg 
Cuvettes (UVette) Carl Roth GmbH & Co. KG, Karlsruhe 
Filter tips (10 µl) Sarstedt AG & Co., Nürnberg 
Filter tips (100 µl, 200 µl, 1000 µl) Kisker Biotech GmbH & Co. KG, Steinfurt 
Flow cytometry tubes Sarstedt AG & Co., Nürnberg 
Fluted filters Sartorius AG, Göttingen 
Glassware Schott AG, Mainz 
Hyperfilm ECL Amersham Biosciences Europe GmbH, Freiburg 
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Miscroscope slides (SuperFrost Plus) Menzel GmbH & Co.KG, Braunschweig 
MMI MembraneSlides Molecular Machines & Industries GmbH, Eching 
MultiScreenHTS-HV plate Millipore GmbH, Schwalbach am Taunus 
Neubauer counting chamber Brand GmbH & Co KG, Wertheim 
Nitrocellulose membrane(Hybond ECL) GE Healthcare Europe GmbH, Freiburg 
NuPAGE Novex 4-12% Bis-Tris Midi Gel Invitrogen GmbH, Karlsruhe 
Pasteur pipettes Brand GmbH & Co.KG, Wertheim 
PCR-Reaction tubes (ThermoFast 96, 
nonskirted, natural domed cap strips, natural) 
Sarstedt AG & Co., Nürnberg 
Petri dishes Ochs GmbH, Bovenden/Lenglern 
Pipette tips (10 µl, 200 µl) Ochs GmbH, Bovenden/Lenglern 
Pipette tips (1000 µl) Sarstedt AG & Co., Nürnberg 
Pipette tips (20 µl) Sarstedt AG & Co., Nürnberg 
Protein concentrators, 20 ml, 9k MWKO  Thermo Fisher Scientific Inc., Waltham, USA 
QPCR Adhesive Clear Seal 4titude Ltd., Berlin 
Scalpel blade #10, #24 Aesculap AG & Co.KG, Tuttlingen 
Serological pipettes (5 ml, 10 ml, 25 ml) Sarstedt AG & Co., Nürnberg 
Sterile filter Omnilab-Krannich, Göttingen 
Syringe 30, 50 ml Terumo Medical Corp., Elkton, USA 
Tissue Culture Plate 6-Well Sarstedt AG & Co., Nürnberg 
Tissue Culture Plate 24-Well Sarstedt AG & Co., Nürnberg 
 
 
III.5 Chemicals and reagents 
All standard chemicals not listed here were obtained from AppliChem GmbH, 
Darmstadt, Carl Roth GmbH & Co. KG, Karlsruhe, or from Sigma-Aldrich 
Chemistry GmbH, Steinheim. 
Table 5: Chemicals and reagents 
Chemicals and reagnets  Supplier  
100 bp plus and 1 kb DNA Ladder Fermentas GmbH, St. Leon-Rot 
Agarose Bio-Budget Technologies GmbH, Krefeld 
BM Purple Roche Diagnostics GmbH, Mannheim 
Boric acid MP Biomedicals LLC, Illkirch, France 
cOmplete, protease inhibitor cocktail Roche Diagnostics GmbH, Mannheim 
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Deoxyribonucleotide triphosphate (dNTP) Roche Diagnostics GmbH, Mannheim 
Dithiotreitol, 100mM (DTT) Invitrogen GmbH, Karlsruhe 
DNase/Rnase-free water GIBCO Invitrogen GmbH, Karlsruhe 
Ethidium bromide (0.07 %) inna-TRAIN-Diagnostics, Kronberg 
EtOH 99 % J.T. Baker B.V., Deventer, Netherlands 
EtOH 99 % denatured CVH Chemie-Vertrieb GmbH & Co. Hannover KG, Hannover 
Formamide Acros Organics b.v.b.a, Geel, Belgium 
Glycergel mounting medium Dako GmbH, Hamburg 
Hematoxilin solution, MAYER Medite GmbH, Burgdorf 
HEPES buffer solution (1M) GIBCO Invitrogen GmbH, Karlsruhe 
I-Block Tropix, Bedford, USA 
Indo-1 AM Thermo Fisher Scientific Inc., Waltham, USA 
ionomycin Sigma-Aldrich Chemistry GmbH, Steinheim 
Matrigel, phenol red free BD Biosciences GmbH, Heidelberg 
NuPAGE MES SDS Running Buffer, 20 x Invitrogen GmbH, Karlsruhe 
PBS-Tablets GIBCO Invitrogen GmbH, Karlsruhe 
Pertex mounting medium Medite Medizintechnik GmbH, Burgdorf 
PhosStop Roche Diagnostics GmbH, Mannheim 
Pluronic F127 Thermo Fisher Scientific Inc., Waltham, USA 
SeeBlue® Plus2 Pre-Stained Standard Invitrogen GmbH, Karlsruhe 
illustra Sephadex G-50 DNA Grade F GE Healthcare Europe GmbH, Freiburg 
TRIzol Reagent Invitrogen GmbH, Karlsruhe 
Xylene J.T. Baker B.V., Deventer, Netherlands 
 
 
III.6 Ready-to-use reaction systems 
Table 6: Ready-to-use reaction systems 
Reaction system  Supplier  
Amersham ECL Plus™ Western Blotting 
Detection Reagents 
GE Healthcare Europe GmbH, Freiburg 
Arcurus Paradise PLUS FFPE RNA Isolation Kit 
(ABI; KIT0312I) 
Thermo Fisher Scientific Inc., Waltham, USA 
BigDye Terminator v3.1 Cycle Sequencing Kit Thermo Fisher Scientific Inc., Waltham, USA 
Cell Proliferation ELISA, BrdU Roche Diagnostics GmbH, Mannheim 
Cell Proliferation Reagent WST-1 Roche Diagnostics GmbH, Mannheim 
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DeadEnd™ Colorimetric TUNEL System Promega GmbH, Mannheim 
Dual-Luciferase Reporter Assay System Promega GmbH, Mannheim 
FITC Annexin V BD Biosciences GmbH, Heidelberg 
HiPure Plasmid DNA Purification Kit Invitrogen GmbH, Karlsruhe 
High Pure PCR Cleanup Micro Kit Roche Diagnostics GmbH, Mannheim 
MicroSpin G50 Columns Amersham Biosciences Europe GmbH, Freiburg 
Pierce BCA Protein Assay Kit Fisher Scientific GmbH,  Schwerte 
Platiunum SYBR Green qPCR SuperMix-UDG 
with ROX 
Invitrogen GmbH, Karlsruhe 
QuantiTect PCR Probe Kit Qiagen GmbH, Hilden 
QuantiTect SYBR Green PCR Qiagen GmbH, Hilden 
Roti-Fect transfection reagent Carl Roth GmbH & Co. KG, Karlsruhe 
RNeasy Fibrous Tissue Kit Qiagen GmbH, Hilden 
SuperScriptII Reverse Transcriptase Invitrogen GmbH, Karlsruhe 
TransIT®-LT1 Transfection Reagent Mirus Bio LLC., Madison, USA 
 
 
III.7 Buffers and solutions 
Buffers and solutions were prepared using double-distilled water. 
 
AEC chromogen, pH 5.2  30 mM acetic acid 
70 mM sodium acetate trihydrate 
16 mM 3-amino-9 ethylcarbazole  
(dissolved in dimethyl formamide) 
 
Blotting buffer  6 % (w/v) Tris base 
 3 % (w/v) glycine 
 0.075 % SDS 
 20 % (v/v) methanol 
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BSA/sodium azide solution 0.1 % (v/v) Tween-20 
 0.02 % (w/v) sodium azide 
 3 % (w/v) BSA 
 in 1 x TBS 
 
Citrate buffer, pH 3.0  10 mM sodium citrate  
 
Citrate buffer, pH 6.0  10 mM sodium citrate  
 
Cresol solution 0.1 % (w/v) Cresol 
in saturated sucrose-solution 
 
Deoxyribonukleotidtriphosphate  10 mM dATP 
(dNTP)-mix 10 mM dTTP 
10 mM dGTP 
10 mM dCTP 
 
DNase I buffer 40 mM Tris-HCl (pH 7.9) 
 10 mM NaCl 
 6 mM MgCl2 
10 mM CaCl2 
 
Eosin 1 % (w/v) eosin y (water soluble) 
80 % (v/v) ethanol 
 
Krebs Ringer solution  10 mM HEPES (pH 7.0) 
140 mM NaCl 
4 mM KCl 
1 mM MgCl2  
1 mM CaCl2 
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Krebs Ringer solution (Ca2+-free) 10 mM HEPES (pH 7.0) 
140 mM NaCl 
4 mM KCl 
1 mM MgCl2  
0.5 mM EGTA 
 10 mM glucose 
 
Modified RIPA buffer 50 mM Tris/HCl pH 7.4 
1% NP-40    
 0.25 % Na-Deoxycholat  
 150 mM NaCl    
1 mM EDTA     
1 protease inhibitor cocktail tablet 
per 10ml  
1 PhosSTOP tablet per 10ml 
 
Paraformaldehyde solution (PFA)  4 % (w/v) Paraformaldehyde 
in 1 x PBS 
 
Phosphate-buffered  1.4 M NaCl 
sodium chloride-solution 27 mM KCl 
(PBS), 10 x, pH 7.4  15 mM KH2PO4 
65 mM Na2HPO4 
 
PBST (washing buffer) 0.1 % (v/v) Tween-20 
 in 1x PBS 
 
Proteinase K buffer  50 mM Tris/HCl pH 8.0 
5 mM EDTA 
 
SDS loading buffer, 6 x 35 % (v/v) glycerol 
in upper gel buffer 9 % (w/v) SDS 
 8.5 % (w/v) DTT 
 0.1 % (w/v) bromophenol blue  
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STE-buffer  50 mM Tris/HCl pH 8.0 
 100 mM NaCl 
1 mM EDTA 
1 % (w/v) SDS 
 
Tris-EDTA buffer pH 9,0 (TE)  10 mM Tris 
1 mM EDTA 
 
Tris-boric acid-EDTA-solution, 890 mM Tris/HCl pH 8.0 
10 x (TBE)  730 mM boric acid 
12.5 mM EDTA 
 
Tris-buffered sodium chloride-solution,  0.5 M Tris/HCl pH 7.4 
10 x (TBS)  1.5 M NaCl 
 
TBST 0.1 % (v/v) Tween-20 
in 1 x TBS  
  
Upper gel buffer 6 % (w/v) Tris base pH 6.8 




III.8.1 Media for bacteria culture 
For cultivation of bacteria (E. coli DH5α, Invitrogen GmbH, Karlsruhe) 
lysogeny broth-medium ((LB-medium;1 % (w/v) tryptone, 0.5 % (w/v) yeast 
extract, 1 % (w/v), NaCl; pH 7.0)) was used. LB-medium was prepared with 
double-distilled water, autoclaved and stored at 4°C. Selection for adequate 
resistance genes was achieved by addition of 100 µg/ml ampicillin (stock 
concentration: 100 mg/ml; Carl Roth GmbH & Co. KG, Karlsruhe) or 50 µg/ml 
kanamycin (stock concentration: 10 mg/ml, Sigma-Aldrich Chemistry GmbH, 
Steinheim)  
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III.8.2 Agar plates 
For preparation of LB-agar plates 1.5 % (w/v) agar was added to LB-medium 
and autoclaved. After cooling down to 55°C the adequate antibiotic 
(100 µg/ml ampicillin or 50 µg/ml kanamycin) was added and LB-agar was 




III.8.3 Media and reagents for cultivation of eukar yotic 
cell lines 
All Media and supplements including antibiotics used for selection of resistant 
clones that were used for cultivation of eukaryotic cell lines are listed in Table 
7. For the preparation of Ca2+-chelexed and heat-inactivated FCS, 50 ml FCS 
were heat-inactivated by incubation for 30 min at 56°C. Afterwards, 10 g 
Chelex 100 were added and stirred for 60 min at room temperature (RT) on a 
magnetic stirrer to eliminate Ca2+-ions. Subsequently, the FCS was sterile 
filtered with an UV-sterilized fluted filter and additionally with a 0.2 µm sterile 
filter and stored at -20°C. 
Table 7: Cell culture media and supplements for euk aryotic cell lines 
Medium or reagent  Supplier  
154CF Medium Gibco, Invitrogen GmbH, Karlsruhe 
Accutase PAA Laboratories GmbH, Pasching 
Chelex 100 Resin Chelating Ion Exchanger Resin BioRad Laboratories Inc., Hercules, USA 
Dulbecco's Modified Eagle Medium (DMEM) Gibco, Invitrogen GmbH, Karlsruhe 
Fetal calf serum (FCS) Gibco, Invitrogen GmbH, Karlsruhe 
G 418 disulfate salt solution (50 mg/ml) Sigma-Aldrich Chemistry GmbH, Steinheim 
HEPES (1M) Gibco, Invitrogen GmbH, Karlsruhe 
Horse serum Gibco, Invitrogen GmbH, Karlsruhe 
RPMI 1640 Medium Gibco, Invitrogen GmbH, Karlsruhe 
Penicillin (10.000 U/ml)/Streptomycin (10 mg/ml) (P/S) PAN Biotech GmbH, Aidenbach 
Puromycin dihydrochloride (10 mg/ml) Sigma-Aldrich Chemistry GmbH, Steinheim 
S.O.C. medium Invitrogen GmbH, Karlsruhe 
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Trypsin/EDTA and TrypLE Express Gibco, Invitrogen GmbH, Karlsruhe 
 
 
III.9 Biological material 
III.9.1  Bacterial strain 




III.9.2 Eukaryotic cell lines 
Eukaryotic cell lines B9, C5N, NIH/3T3, NIH/3T3-Wnt5a, HEK-293 and 
Wnt-3A L and L cells were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10 % FCS and 1 % penicillin/streptomycin (P/S). 
The cell line ASZ001 was cultured in medium 154CF containing 0.05 M 
CaCl2, 2 % heat-inactivated and Ca
2+-chelexed FCS and 1 % P/S. The 
respective stably transfected cell lines were cultured in the presence of an 
adequate antibiotic (see Table 8). 
Table 8: Eukaryotic cell lines 
1: Designation of cell line; 2: Origin of cell line; 3: Culture medium; 4: Source of cell line/reference; Abbreviations: 
BCC: basal cell carcinoma; FCS: fetal calf serum; P/S: penicillin/streptomycin; DMEM: Dulbecco`s Modified Eagle 
Medium; Wnt3a: wingless-related MMTV integration site 3A;  
1 2 3 4 
ASZ001 murine BCC 
154CF, 2 % chelexed 
FCS, 1 % P/S 




DMEM, 10% FCS, 1 % 
P/S 
F. Nitzki, dissertation, 2008 
C5N murine keratinocytes 
DMEM (lacking 
pyruvate), 10% FCS, 1 
% P/S 




DMEM, 10% FCS, 1 % 
P/S 
ATCC LGC Promochem, Wesel; CRL-
1573  
L929 murine fibroblast 
RPMI 1640 10% FCS, 1 
% P/S 
85011425, Sigma Aldrich Chemistry 
GmbH, Steinheim 
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L cells murine  fibroblasts 
DMEM, 10% FCS, 1 % 
P/S 
ATCC®  CRL-2648™  





DMEM, 10% FCS, 1 % 
P/S, 0.4 µg/ml G418 




DMEM, 10% FCS, 1 % 
P/S 




see above, stably 
overexpressing Wnt5a 
DMEM, 10% FCS, 1 % 
P/S, 0.4 µg/ml G418 




DMEM, 10% FCS),  
1 µg/mL puromycin,  
10µg/mL blasticidin,  
1% P/S 
RV-101, cell biolabs, Inc. 
 
 
III.9.3 Mouse lines 
Table 9: Mouse lines 
1: Designation of mouse line; 2: strain background; 3: Genetic modification and use; 4: Source 
1 2 3 4 




Floxed exons 8 and 9 of the murine 
Ptch gene; for conditional 
Ptch gene deletion 





recombinase expression under control of 
ROSA26 promotor 





Tau-LacZ reporter cassette integrated in Exon 1 
causes a frameshift and thereby abrogates Wif1 
expression 
(Kansara et al. 2009) 
 
All experiments using animals were performed in compliance with all legal 
and ethical requirements.  
 
 
III.10  Plasmids 
Plasmids listed in Table 9 were either used for transfection, nucleofection or 
transduction of eukaryotic cell lines. 
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Table 10: Plasmids 
1: Designation of vector; 2: Purpose; 3: Designation of vector backbone if different from 1; 4: Supplier of vector 
backbone or reference (if applicable);  
1 2 3 4 
pCR3.1 Dual-Luciferase assay  Invitrogen GmbH, Karlsruhe 
pCl-neo-β-cateninS33Y Dual-Luciferase assay pCI-neo (Morin et al. 1997) 
pcDNA3-Wif1 Wif1 overexpression pcDNA3 (Becker  2011) 




 Clontech Laboratories, Inc. 
pMSCVpuro-Wif1 Wif1 overexpression pMSCVpuro this thesis 
pRL-CMV Dual-Luciferase assay  Promega GmbH, Mannheim 
SuperTOPFlash Dual-Luciferase assay pTA-Luc (Korinek et al. 1997) 









III.11 Synthetic oligonucleotides 
Synthetic DNA-oligonucleotides were ordered from Eurofins MWG Operon, 
Ebersberg. The stock concentration of DNA-oligonucleotides was set to 
100 µM using RNase- and DNase-free water. For all PCR reactions a 10 µM 
solution was used. 
 
 
III.11.1 Synthetic DNA-oligonucleotides for qRT-PCR  
Since embryos express of a broad range of genes, cDNAs made from mouse 
embryos of different ages (see Table 11) were used a) to establish the 
qRT-PCR assay for the expression analysis of a specific gene and b) to set 
up the standard curve to calculate the expression level of the respective 
gene. The age of an embryo used for the synthesis of cDNA was chosen 
according to the expression profile of respective mRNA reported in the 
database MGI and Expression Atlas.  
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Table 11: Oligonucleotides for qRT-PCR analyses 
1: Designation of analysed transcript; 2: Designation of oligonucleotides; 3: Oligonucleotide sequence (5’→3’); 4: 
control cDNAs, 10.5, 12.5, 13.5: Age of mouse embryos in days post coitum (dpc) for generation of control cDNA, 
BCC: Basal Cell Carcinoma, HEK LiCl: HEK-293 treated for 12 h with 50 nM LiCl; 5: References; 6: Supplier of 
utilized SYBR Green (determining program used, see. III.14.2.3). 



































































































































































this thesis Qiagen 
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III.11.2 Synthetic DNA-oligonucleotides for cloning  
The DNA-oligonucleotides listed in Table 12 were used for the cloning of a 
mWif1 expression vector. 
Table 12: Oligonucleotides for cloning 
1: Designation of synthetic DNA-oligonucleotide; 2: nucleotide sequence of oligonucleotides (5’→3’); 3: Reference. 





mWif1-HpaI-R CGTTAACTCACCAGATGTAATTGGATTC this thesis 
 
 
III.11.3 Synthetic DNA-oligonucleotides for sequenc ing 
The primers listed in Table 13 were used for sequencing of the mWif1 insert 
cloned into pMSCVpuro expression vector. 
Table 13: Oligonucleotides for sequencing of mWif1 
1: Designation of oligonucleotide; 2: Nucleotide sequence of oligonucleotides; 3:Reference. 
1 2 3 
mWif1-F TCCTGTCAATATCCACTCCATGAA König 2012 
mWif1-intraF1 AAGGAGACCTGTGCTCTAAGC this thesis 
mWif1-R CTGATGCCTTGTGAGGCACT König 2012 
mWif1-seq-rv1 CCTCCATTTCGGCAGGGTTGG this thesis 
mWif1-tq-F CGCCCATCAGGCTAGAGTGC Ecke 2008 
mWif1-tq-R GACAGGAATGGCTGGCATTCT Ecke 2008 
 
 
III.11.4 Synthetic DNA-oligonucleotides for genotyp ing 
Table 14: Oligonucleotides for genotyping 
1: Designation of analyzed allele; 2: Designation of oligonucleotide nucleotide; 3: Sequence of oligonucleotides; 
4: Reference. 












(Uhmann et al. 2007) 




































All enzymes were used with appropriate buffers and according to 
manufacturer`s protocol. 
Table 15: Enzymes 
Enzyme  Supplier  
BglII Invitrogen GmbH, Karlsruhe 
HindIII Invitrogen GmbH, Karlsruhe 
DNase I Qiagen GmbH, Hilden 
Phusion DNA Polymerase New England Biolabs GmbH, Frankfurt am Main 
Proteinase K Carl Roth GmbH & Co. KG, Karlsruhe 
RNase A Carl Roth GmbH & Co. KG, Karlsruhe 
RQ1-DNase Promega GmbH, Mannheim 
SuperScriptII Reverse Transcriptase Invitrogen GmbH, Karlsruhe 
T4 DNA Ligase Invitrogen GmbH, Karlsruhe 
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III.13  Antibodies 
III.13.1 Primary antibodies 
Table 16: Primary antibodies for immunohistochemist ry 
1: Designation; 2: Source; 3: Dilution; 4: Antigen retrieval; 5: Supplier. 





TE, pH 9.0, 
microwave 






boric acid, pH 5.1, 
30 min 60°C 





TE, pH 9.0, 
microwave 











Citrate, pH 6.0, 
microwave 
Becton Dickinson GmbH, Heidelberg 





TE, pH 9.0, 
microwave 
Leica Biosystems Nussloch GmbH, 
Nussloch 
Anti-Acta2 1A4 (Sma) 
mouse, 
monoclonal 







TE, pH 9.0, 
microwave 
Abcam plc., Cambridge, UK 
 
 
Table 17: Primary antibodies for Western blot 










New England Biolabs GmbH, Frankfurt 
am Main 
anti-Bcl-2, Clone: 6C8 
rabbit, 
polyclonal 




1:1000 Becton Dickinson GmbH, Heidelberg 
Phospho-CaMKII 










New England Biolabs GmbH, Frankfurt 
am Main 
cyclin E (M20) 
rabbit, 
polyclonal 
1:200 Santa Cruz Biotechnology, Inc. Heidelberg 













New England Biolabs GmbH, Frankfurt 
am Main 
Phospho-c-Jun 




New England Biolabs GmbH, Frankfurt 
am Main 





1:1000 Sigma Aldrich Chemistry GmbH, 
Steinheim 





New England Biolabs GmbH, Frankfurt 
am Main 
HSC 70 (B-6): sc-7298 
mouse, 
monoclonal 
1:10000 Santa Cruz Biotechnology, Inc. Heidelberg 
Phospho-PKC (pan) 




New England Biolabs GmbH, Frankfurt 
am Main 













New England Biolabs GmbH, Frankfurt 
am Main 
Anti-Acta2 1A4 (Sma) 
mouse, 
monoclonal 
1:50 Beckman Coulter Inc., Brea, USA 
Syndecan 2 antibody 
rabbit, 
polyclonal 






1:1000 Abcam plc., Cambridge, UK 
 
 
III.13.2 Secondary antibodies 
Table 18: Secondary antibodies  
1: Designation; 2: Source; 3: Specificity; 4: Application; 5: Supplier. 
1 2 3 4 5 
ECL Anti-Mouse IgG, Horseradish Peroxidase-





Europe GmbH, Freiburg 





Sigma Aldrich Chemistry 
GmbH, Steinheim 
EnVision™/HRP, Rabbit/Mouse (ENV) goat 
rabbit, 
mouse 
IHC Dako GmbH, Hamburg 
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Anti-Rabbit Immunoglobulins/AP (D 0487) goat rabbit IHC Dako GmbH, Hamburg 
donkey anti-goat IgG (H+L) (clone: pAK)-HRPO donkey goat IHC 
Dianova GmbH, 
Hamburg 
Biotinylated Rabbit Anti-Rat IgG Antibody  
(BA-4001) 
rabbit rat IHC 
Biozol Diagnostica 
Vertrieb GmbH, Eching 
Streptavidin/HRP (P0397)   IHC Dako GmbH, Hamburg 
 
 
III.14 Molecular biological methods 




III.14.1 Isolation of nucleic acids 
III.14.1.1  Isolation of plasmid DNA from bacteria  
For small- and medium-scale isolation of plasmid DNA from bacteria the 




III.14.1.2  Isopropanol/ethanol precipitation of nu cleic 
acids  
2 volumes of 100% ethanol or alternatively an equal volume of isopropanol 
were added to the nucleic acid solution, thoroughly mixed and precipitated 
overnight at -20°C. Then, solution was centrifuged for 30 min at 16000 x g 
and 4°C. The pellet was washed twice with 70 % EtOH for 10 min, 4°C and 
16000 x g, air dried and dissolved in DNase/RNase-free water and the 
DNA/RNA concentration was measured via photometer (Eppendorf). 
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III.14.1.3 Isolation of total RNA from embryonic ti ssue  
To isolate total RNA from embryos tissue was minced with a scalpel blade, 
homogenized 60 sec in 1 ml Trizol on ice, incubated for 5 min at room 
temperature (RT) and mixed with 200 µl chloroform. The mixtures were 
vortexed, incubated for 3 min at RT and centrifuged for 10 min at 4°C and 
800 x g. Afterwards, the upper phase was precipitated with 500 µl 
isopropanol overnight at -20°C and centrifuged for 30 min at 16000 x g and 
4°C. The pellet was washed twice with 70 % EtOH for 10 min, 4°C and 
16000 x g, air dried and dissolved in RNase-free water and the RNA 
concentration was measured via photometer (Eppendorf). 
 
 
III.14.1.4 Isolation of total RNA from murine tissu e 
RNA from skin samples was isolated using the RNeasy Fibrous Tissue Kit 
(Qiagen) following the manufacturer’s instructions. Subsequently, the 
samples were incubated with DNase I (Qiagen). For this purpose, 10 % (v/v) 
RDD-buffer (supplied with DNase I) and 0.14 U/µl DNase I were added to the 
RNA, incubated 1 h at 37°C and then for 5 min at 65°C. RNA was 
precipitated using 99% EtOH overnight at -20°C, centrifuged at 16000 x g for 
35 min and washed with 70 % EtOH. The pellet was dissolved in 20 µl 




III.14.1.5 Isolation of total RNA from cell culture  
Cells were rinsed with 1 x PBS and detached in 1 ml TRIzol by pipetting. To 
avoid RNA degradation the subsequent steps were performed on ice, unless 
stated otherwise. Samples were vortexed for 2 min and then incubated for 5 
min at RT. Subsequently, 200 µl of chloroform were added followed by 
vortexing for 15 sec and an incubation step for 3 min at RT. Afterwards, the 
mixture was centrifuged for 10 min at 6000 x g and 4°C. The upper phase 
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containing the RNA was transferred into a new 1.5 ml E-cup containing 1 ml 
isopropyl alcohol, inverted and precipitated overnight at -20°C. Subsequently, 
the mixture was centrifuged for 30 min at 10000 x g and 4°C. The 
supernatant was discarded and the remaining pellet was washed with 1 ml 
70 % EtOH (-20°C) by centrifugation for 10 min at 10000 x g and 4°C. 
Afterwards, supernatant was removed and the pellet was air-dried at RT. 
Subsequently, the pellet was dissolved in 20 µl RNase-free H2O for 5-10 min 




III.14.1.6 Laser microdissection  
For the microdissection 10 µm paraffin sections were cut using a microtome, 
transferred to MMI membrane slides, dried for 30 min at 37°C and frozen at -
80°C. After thawing, sections were deparaffinized with xylene and rehydrated 
using descending ethanol series. To stain the nuclei the sections were 
incubated in hemalaun solution and 0.1% NaHCO3 solution was added. After 
the staining reaction sections were dehydrated by ascending ethanol series 
and transferred in xylene. Laser microdissection was subsequently 
performed using MMI CellCut and MMI CellTools software and RNA was 
isolated with Arcturus Paradise PLUS FFPE RNA Isolation Kit according to 
the manufacturer`s protocol. 
 
 
III.14.1.7 Photometric quantification of nucleic ac ids  
1 µl of sample DNA or RNA was dissolved in 99 µl water (1:100 dilution) and 
transferred into a cuvette. The concentration of nucleic acids was measured 
using a photometer at a wavelength of 260nm to quantify the DNA/RNA and 
at a wavelength of 280 nm to determine the purity of the sample. Pure DNA 
or RNA sample have a 260/280 ratio of 1.8 and 2.0, respectively, and are 
relatively free from protein contamination. DNA or RNA concentrations can 
be estimated by measuring the absorbance at 260nm (A260), adjusting the 
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A260 measurement for turbidity (measured by absorbance at 320nm), 
multiplying by the dilution factor, and using the relationship that an 
A260 of 1.0 equates 50 µg/ml pure DNA or A260 of 1.0 equates 40 µg/ml pure 
RNA. The concentration thus can be calculated according to the following 
formula:  
concentration (µg/ml) = (A260 reading – A320 reading) × dilution factor × 50 (or 
40) µg/ml.  
 
 
III.14.2 Polymerase chain reaction 
III.14.2.1 Reverse transcription  
Reverse transcription of RNA was performed in a final volume of 20 µl. 
250 ng hexamers were added to 2 µg total RNA and the mixture was 
incubated for 10 min at 70°C. Afterwards, 1 x 1st strand buffer (Invitrogen), 
10mM DTT (Invitrogen) and 0.5mM dNTPs were added and the mixture was 
incubated at 25°C for 10 min and at 42°C for 2 min. Subsequently, 1 µl (200 
U/µl) SuperScript II Reverse Transcriptase (Invitrogen) was added and 
mixtures were incubated for 1 h at 42°C, followed by incubation at 70°C for 
10 min. The efficiency of the reverse transcription is empirically 50%, thus 
resulting in 1 µg cDNA when 2 µg RNA is reversely transcribed. 
 
 
III.14.2.2 Polymerase chain reaction of cDNA  
The amplification of cDNA in reaction volumes of 10-20 µl was performed 
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10-100 ng template-cDNA 
0.5 µM sequence-specific forward-DNA-oligonucleotides 
0.5 µM sequence-specific reverse-DNA-oligonucleotides 
0.2 mM dNTP-mix 
1 % (v/v) N.N.-dimethyl sulfoxide (DMSO) 
10 % (v/v) cresol solution 
1 x polymerase-buffer 
0.1 U Taq-polymerase (Molzym) 
 
PCR-conditions varied depending on utilized DNA-oligonucleotides and 
amplified fragment sizes. Usually the following conditions were applied: 
5 min   95°C 
30 sec  95°C 
1 min   58°C      27 cycles 
1 min   72°C  
5 min   72°C 
∞  8°C 
The results were visualized by agarose gel electrophoresis. 
 
 
III.14.2.3 Quantitative real-time PCR (qRT-PCR)  
The expression levels of different genes in allografts and BCCs were 
measured by means of qRT-PCR using SYBR Green (SYBR Green I, 
Invitrogen or QuantiTect SYBR Green, Qiagen). Genes analyzed were Axin2, 
c-myelocytomatosis oncogene (c-Myc), cadherin 1 and 2 (Cdh1 and 2), 
fibronectin 1 (Fn1), Glioma-associated oncogene family member 1 (Gli1), 
keratin 1 and 10 (K1 and K10), involucrin (Ivl), loricrin (Lor), and Wnt 
inhibitory factor-1 (Wif1). The expression of these genes was measured 
using 5 ng cDNA derived from allografts and human or murine BCC samples. 
For normalization the expression of the hypoxanthine guanine 
phosphoribosyl transferase (Hprt) and TATA box binding protein (Tbp) was 
measured in 5 ng cDNA. Alternatively, the expression of 18S rRNA in 16 pg 
cDNA of each sample was measured. All oligonucleotides used are listed in 
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Table 11. For qRT-PCR analyses SYBR Green from Invitrogen or Qiagen 
was used at the following conditions.  
 
Qiagen:   50°C for 2 min 
95°C for 15 min 
               95°C for 15 sec 
             60°C for 30 sec 
             72°C for 30 sec 
 
Invitrogen:   50°C for 2 min  
94°C for 2 min  
94°C for 15 sec 
60°C for 1 min 
 
For both reactions the following reagents were used in a total volume of 
10 µl:  
2.5 ng template-cDNA 
0.4 µM sequence-specific forward-DNA-oligonucleotides 
0.4 µM sequence-specific reverse-DNA-oligonucleotides 
1 x SYBR Green master mix (containing HotStarTaq DNA 
Polymerase [Qiagen] or Platinum Taq DNA Polymerase 
[Invitrogen], SYBR Green PCR Buffer, dNTP mix, SYBR Green 
dye and ROX dye) 
 
As data were analyzed by the standard curve method a standard curve with 
cDNA was compiled for each measurement. For this purpose, a series of 
seven 1:5 dilutions (S1-S7) was set up and amplified for each analysis. cDNA 
with a concentration of 10 ng/µl for S1 from mouse BCCs, embryos isolated 
at either 13.5, 12.5 or 10.5 days post coitum (dpc) or HEK-293 cells treated 
with LiCl was used (see Table 11). The ABI Prism 7900HT Sequence 
Detection System was used for all qRT-PCR analyses. Each sample was 
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III.14.2.3.1 Data analysis using the standard curve  method  
The results were analyzed using SDS 2.2.1 (Applied Biosystems) and 
Microsoft EXCEL (Microsoft Co) softwares. The standard was set up by a 
serial 1:5 dilution. For correct analysis the amplification curve ought to be in 
the exponential phase of the reaction when the Ct was achieved. Based on 
the determined values of the standard curve a standard line was compiled by 
plotting the logarithm of the quantity of cDNA against the Ct-value for each 
dilution. Thus, the standard line follows the equation y = mx + b. With this 
equation the expression level of each analyzed gene was determined in each 
sample. Each sample was normalized to the endogenous control (Hprt, Tbp, 
or 18S rRNA, respectively).  
 
 
III.14.3 Cloning techniques 
III.14.3.1 Restriction hydrolysis  
Restriction hydrolyses of DNA were performed in volumes of 10 µl at 37°C 
for 2 h. 1 µg DNA was hydrolyzed with 3 units (U) of adequate restriction 
endonuclease. If possible, simultaneous hydrolysis of a DNA sample with two 
different enzymes was performed using a buffer ensuring optimal conditions 
for both enzymes. Alternatively, a serial restriction hydrolysis was performed. 
For this purpose, the DNA sample was first hydrolyzed for 1h at 37°C using 
the first restriction endonuclease that has the lowest salt concentration in its 
recommended buffer. Subsequently, salt concentration was adjusted for the 
second reaction. Then, the second restriction endonuclease was added and 
incubated for 1h at 37°C. Restriction hydrolysis was stopped by heat-
inactivation if applicable. 
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III.14.3.2 Isolation of DNA fragments from agarose gels  
DNA fragments from agarose gels were excised under UV-light using a 
sterile scalpel blade and were extracted from the gel using the High Pure 
PCR Cleanup Micro Kit according to the manufacturer’s instructions.  
 
 
III.14.3.3 Ligation  
Ligation of DNA fragments was performed using T4 DNA Ligase as it is 
capable of catalyzing the ligation of two DNA double-strands in the presence 
of ATP between the 5´-phosphate and the 3´-hydroxyl groups of adjacent 
nucleotides in either a cohesive-ended or blunt-ended configuration. Ligation 
was conducted using 1 x ligation buffer and 4 U T4 DNA ligase (Invitrogen) in 
a total reaction volume of 20 µl. The amount of insert per ng of vector used 
was estimated from the gel and calculated according to the formula: 
 ng of insert≈
length of insert×(ng of vector)
(length of vector)
×molar ratio  insert
vector
 
The molar ratio of insert to vector (100-200 ng) was set 3 to 1.  
 
 
III.14.3.4 DNA-sequencing  
For cycle-sequencing of pMSCVpuro-mWif1 500 ng of the plasmid, 1 µM 
primer (see Table 13), 1 x Sequencing Buffer, 1 µl BigDye® Terminator v3.1 
Ready Reaction Mix were used in a total reaction volume of 10 µl. The 
following cycler program was used:   
1 min  95°C 
     30 sec 95°C 
     2.5 min 60°C 
     5 min  60°C 
     ∞  10°C 
Amplificates were purified using Sephadex G-50 in a MultiScreenHTS-HV 
plate and the analysis of the sequence was performed on a ABI 3500 XL 
30 x 
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genetic analyzer and ABI 3500 data collection software. Further analysis was 
performed with the Sequencing Analysis Software v5.4 and BioEdit software. 
 
 
III.14.3.5 Cloning of a Wif1 expression plasmid  
A Wif1 expression plasmid was generated by inserting the mWif1 cDNA 
amplified from pcDNA3-mWif1 (Becker 2011) in the vector backbone 
pMSCVpuro. 
At first, the mWif1 insert was generated by means of PCR using a forward 
primer containing a BglII recognition sequence and a Kozak consensus 
sequence, and a reverse primer containing an HpaI recognition sequence 
(see Table 12). Integrity of the amplicon was determined by gel 
electrophoresis. A band of 1156 bp was generated as expected and purified 
from the agarose gel (see section III.14.3.2 and Fig. 5).  
 
Fig. 5: Gel electrophoresis of amplified and purifi ed Wif1 insert 
Insert is 1156 bp long containing BglII recognition sequence, a Kozak consensus sequence, the 1140 bp coding 
sequence and an HpaI recognition sequence. 
 
Then, insert and pMSCVpuro were hydrolyzed with restriction endonulceases 
BglII and HpaI, purified by ethanol precipitation (see II.14.X) and dissolved in 
20µl ddH2O. 2 µl of each 20 µl DNA solution was analyzed by gel 
electrophoresis (see Fig. 6). The concentration of DNA solutions was 
estimated by comparing the respective band intensity with band intensity of 
neighboring DNA ladder having a known DNA concentration.  




Fig. 6: Gel electrophoresis of hydrolyzed Wif1 insert and pMSCV vector backbone 
Insert is 1156 bp long containing BglII recognition sequence, a Kozak consensus sequence, the 1140 bp coding 
sequence and an HpaI recognition sequence. pMSCV vector backbone has a given size of 6.3 kb. 
 
Subsequently, a 3:1 ratio of the insert to vector DNA was used for ligation 
(see III.14.3.3) and transformed into E. coli (see III.14.4.1). Single cell clones 
were picked for small-scale isolation of plasmid DNA from bacteria culture 
(see III.14.1.1). A total number of 18 clones were isolated. Successful cloning 
of pMSCVpuro-Wif1 was verified by restriction hydrolyses (see III.14.3.1) and 
DNA sequencing (see III.14.3.4) (see Fig.7 and data not shown). By using 
BglII and HpaI only plasmids containing the full-length insert are hydrolyzed 
resulting in a 1.2 kb (mWif1-insert) and a 6.3 kb (pMSCVpuro) fragment (top 
panel). Using HindIII and BamHI the orientation of the inserts was 
determined. In a 5ʼ→3ʼ orientation two fragments of 560 bp and 6.9 kb length 
were generated. When inserts were in 3ʼ→5ʼ orientation restriction hydrolysis 
would result in fragments of 1.6 and 5.7 kb length (bottom panel). 




Fig. 7: Gel electrophoresis of restriction hydrolyz ed pMSCV-Wif1 
18 clones were picked from agar plates for downstream analysis. Top: Use of restriction enzymes BglII and HpaI 
result in the generation of a 1.2 kb and a 6.3 bp fragment. Bottom: An insertion in 5ʼ→3ʼ orientation resulted in two 
fragments of 560 bp and 6.9 kb length when hydrolyzed with HindIII and BamHI. A 3ʼ→5ʼ orientation would result in 
fragments of 1.6 and 5.7 kb length.  
 
The 2 clones #10 and #13 were shown to have the insert in the correct 
orientation. All following experiments were performed with plasmid derived 
from clone #10. The plasmid pMSCVpuro-mWif1 (hereafter pMSCV-Wif1) 
was transfected in the packaging cell line Platinum-E for the production of 
retroviral particles (see III.14.4.8). 
 
 
III.14.4 Cell biological techniques 
III.14.4.1 Transformation of bacteria  
100 ng plasmid was added to 50 µl competent cells (DH5α) and incubated for 
20 min on ice. Afterwards, bacteria were transformed by heat-shock for 45 
sec at 42°C and chilled on ice for 2 min. Subsequently, 500 µl SOC-medium 
were added and cells were incubated for 1 h at 37°C and 900 rpm on a 
heating block. 50 µl of the bacterial solution were plated on an agarose plate 
containing adequate antibiotics (1 µg/ml) and incubated overnight (O/N) at 
37°C. 
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III.14.4.2 Culture of eukaryotic cells  
Cells were cultured in an incubator at 5% CO2, 90% humidity and 37°C. 
Medium was changed every three days and cells were subcultured by 
splitting them 1:10 upon reaching 70-80% confluence. Culture of cells was 
performed using media listed in Table 8. 
 
 
III.14.4.3 Isolation and cultivation of BMDMs  
To isolate bone marrow-derived macrophages (BMDMs) the femur of a wt 
mouse was excised and the attached connective and muscle tissue was 
removed. Both ends of the femur were cut by scissors and macrophages of 
the bone marrow were expelled in a petri dish using a syringe and 10 ml 
Pluznik medium (DMEM/10 % FCS/5 % horse serum/30 % L929 CM/1 % 
P/S/0.0002 % β-mercaptoethanol). L929 CM was prepared as described in 
section II.14.4.4.2. Afterwards, cells were incubated O/N at 37°C, 5 % CO2 
and 95 % humidity. The Supernatant containing the unattached 
macrophages was centrifuged for 10 min at 800 x g, the cell pellet was 
dissolved in 40 ml Pluznik medium, split and subcultivated in 4 uncoated petri 
dishes. The culture medium was changed every third day. 7 days after the 
isolation of BMDMs, cells were detached from petri dishes using Accutase 
and used for coculture proliferation assay (see section III. 14.4.10.2) 
 
 
III.14.4.4 Conditioned media (CM)  
III.14.4.4.1 Generation and use of Wnt3a and Wnt5a CM 
NIH/3T3 Wnt5a, NIH/3T3, L Wnt-3A and L cells were cultured as described in 
section III.14.4.2. Cells that were 70 % confluent were subcultured by 
splitting them 1:10 in media without selective antibiotics. After 4 days the first 
fraction of the conditioned medium was collected and new medium was 
added for additional 3 days for the production of the second fraction. The 2 
conditioned media fractions were combined and centrifuged at 1000 x g for 5 
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min to eliminate remaining cells and the supernatant was subsequently 
sterile filtered through 0.2 µm filters and stored at 4°C.  
 
 
III.14.4.4.2 Generation and use of L929 CM  
L929 conditioned medium was prepared from L929 cells having an initial 
50% confluency and which were cultured 5 days in RPMI/10 % FCS/1 % PS. 
Subsequently, the medium was collected and sterile filtered with a 0.2 µm 




III.14.4.5 Concentration of Wif1-containing media  
ASZ-pMSCV and ASZ-Wif1 cells were split 1:10 after reaching 70-80 % 
confluency and transferred in fresh culture medium without puromycin. After 
5 days the medium was removed and replaced with fresh culture medium for 
5 additional days. Both supernatants were subsequently centrifuged at 
4500 x g for 10 min to remove all cells and debris. Afterwards, the 
supernatants were transferred to a protein concentrator tube (Thermo Fisher 
Scientific). Concentrator was used according to manufacturers` protocol 
generating a 75-fold concentrated supernatant. 
 
 
III.14.4.6 Transfection of eukaryotic cells  
HEK-293 cells were seeded in 6-well plates (105 cells/well) in 1 ml of the 
respective culture medium (see Table 8). 24 h later 1 - 2.2 µg plasmid DNA 
and Roti-Fect (Carl Roth) transfection reagent (5 µl per 1 µg DNA) were 
added to 100 µl DMEM and incubated for 40 min at RT to allow for nucleic 
acid-lipid complex formation. Subsequently, the mixture was added to the 
cells cultured in 1 ml of fresh culture medium without P/S for 3 h. Thereafter, 
the cells were washed and incubated with the respective culture medium for 
24 h. 
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III.14.4.7 Nucleofection of eukaryotic cells  
For nucleofection 2·106 ASZ001 cells were centrifuged at 90 x g for 10 min. 
2.5 µg total plasmid (see scheme below) or 1µg nucleofection control plasmid 
(pGFPmax) in 100 µl Nucleofector solution was added to the cell pellet and 
cells were resuspended. Then, cells were transferred into an electroporation 
cuvette and nucleofected using program T-029 in the electroporation device 
Amaxa Nucleofector 2b (Lonza). Afterwards, 100 µl of nucleofected cells 
were directly plated in 96-well plates for downstream analysis via TOP/FOP 
reporter assay (see III.14.4.9). 
Table 19: Scheme of plasmid combinations for nucleo fection 
1: 1st plasmid (200 ng) ; 2: 2nd plasmid (1 µg); 3: 3rd plasmid (1 µg) 
1 2 3 
pRL-CMV SuperTOPFlash (TOP) pCl-neo-β-catS33Y 
pRL-CMV SuperTOPFlash (TOP) pCR3.1 
pRL-CMV SuperFOPFlash (FOP) pCl-neo-β-catS33Y 
pRL-CMV SuperFOPFlash (FOP) pCR3.1 
- pGFP-max - 
 
 
III.14.4.8 Retroviral transduction of eukaryotic ce lls  
For preparation of virus particles used for transduction of ASZ001 cells 
Platinum-E cells were used as packaging cell line. Platinum-E cells were 
seeded at a confluency of 70 % in 5 cm culture dishes one day before 
transfection with the retroviral vectors. For the transfection the following 
reagents were used: 
 
400 µl serum free medium (154 CF) 
9 µl TransIT®-LT1 Transfection Reagent  
3 µg retroviral expression vector  
(pMSCVpuro or pMSCVpuro-Wif1, respectively) 
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The reagents were mixed and incubated at RT for 30 min. Afterwards, the 
Platinum-E cells were washed and the medium was replaced with 4 ml fresh 
culture medium (154CF, 2% FCS, 1% P/S). The transfection mixture was 
added drop wise onto the plates and mixed by swirling. After 48 h the cell 
supernatants containing the viruses were sterile-filtered using a 0.45 µm pore 
sterile filter. 3 ml supernatant was mixed with 3 ml fresh medium containing 3 
µg/ml polybrene and applied to a 5 cm culture dish containing 50 % confluent 
ASZ001 cells. After 24 h the cells were washed and supplied with fresh 




III.14.4.9 TOP/FOP reporter assay  
The β-catenin dependent activity of Wnt signaling was analyzed using a dual 
luciferase reporter assay. HEK-293 ells were seeded at a density of 1.5·105 
cells/well in a 6-well plate. 24 h later cells were transfected with 1 µg of either 
SuperTOPFlash (TOP) plasmid containing multiple T cell-specific 
transcription factor/lymphoid enhancer-binding factor (TCF/LEF)-binding sites 
or its negative control vector SuperFOPFlash (FOP) containing mutated and 
thereby inoperable binding sites (1 µg). 200 ng of the renilla-luciferase 
encoding plasmid pRL-CMV was cotransfected for normalization. 
Cotransfection with 1 µg pCl-neo-β-catS33Y encoding for a constitutively 
active β-catenin served as positive control. In all settings, the final amount of 
DNA was increased to a total of 2.2 µg with pCR3.1 vector DNA. 24 h after 
transfection (see section III.14.4.6) cells were trypsinized and 6000 cells 
were subcultured in 96 well plates with Wnt3a CM or control medium. To 
block Wnt3a, Wnt3a CM was supplemented with 600 ng/ml Dkk1 or was 
preincubated with an equal volume of 75 x concentrated ASZ-Wif1, 
ASZ-pMSCV (control) conditioned medium or with 30 µg/ml rWnt3a, 
respectively, for 5 h at RT and 450 rpm and then added to the transfected 
HEK-293 cells. After additional 48 h, cells were lysed and renilla- and firefly-
luciferase activity was measured using the Dual-Luciferase Reporter Assay 
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III.14.4.10 Proliferation assay  
III.14.4.10.1 5-Bromo-2`-deoxyuridine assay 
8000 cells were seeded in a 96 well plate 24 h before BrdU labeling. The 
BrdU labeling was performed for 24 h according to manufacturer`s protocol 
(Roche).  
The measurement was conducted by means of a plate reader (Synergy MX). 
 
 
III.14.4.10.2 Coculture proliferation assay  
On the first day 4 x 104 cells of the cell lines ASZ-pMSCV or ASZ-Wif1 were 
seeded in each well of a 24-well plate and 5 x 104  bone marrow derived 
macrophages (BMDMs), B9, NIH/3T3, NIH3T3-Wnt5a, Wnt-3A or L cells 
were seeded in 24-well inserts (0.2 µm pore size) placed in 24-well plates for 
coculture proliferation measurement. On each of 5 consecutive days the total 
cell number per well was counted using Celigo S device and software. 
 
 
III.14.4.11 Cell cycle analysis  
For cell cycle analysis 1·106 cells were subcultivated in 10 mm culture dishes. 
After 48 h the cells were detached using Accutase and transferred into a 
15 ml tube containing 5 ml Medium. Then, cells were washed by 
centrifugation for 5 min at 300 x g and 4°C and resuspended in 1ml PBS. 
Subsequently, the cell suspension was mixed with 10 ml -80°C 
100 % ethanol. Afterwards, the cells were fixed for 2 h at –20°C. Then, cells 
were centrifuged for 5 min at 1000 x g and 4°C and washed with 2 ml 
100 % Ethanol by additional centrifugation for 5 min at 1000 x g and 4°C. 
Subsequently, the cell pellet was resuspended in 500µl propidium iodide 
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solution (10 µg/ml propidium iodide and 100 µg/ml RNaseA in PBS) and 
incubated for 30 min at 37°C. Afterwards, cells were analyzed using the flow 
cytometer LSR II (BD Biosciences) and FacsDivaTM (BD Biosciences) and 
FlowJo softwares (Tristar, Inc.), respectively. 
  
 
III.14.4.12 Cell viability assay  
8000 cells were seeded in a 96 well plate 24 h before adding WST-1. WST-1 
was added for 4h. 200 mM H2O2 was added as negative control. The 
measurement was conducted by means of a plate reader (Synergy MX). 




III.14.4.13 Annexin V assay  
When in the early phase of apoptosis the integrity of the plasma membrane 
gets lost, phosphatidylserine translocates from the inner side of the plasma 
membrane to the cell surface. Annexin V is a Ca2+-dependent protein that 
can bind to PS. FITC coupled Annexin V was used to detect apoptosis and 
propidium iodide (PI) was used to identify necrotic cells. 
Cells were detached using 1 ml Accutase and washed with 1 x PBS by 
centrifugation at 300 x g for 5 min. Afterwards, the cell pellet was 
resuspended in 100 µl 1 x Annexin V-binding buffer containing 2 µl 
Annexin V-FITC for 10 min. Subsequently, 2 µl of a 100 µg/ml PI solution 
was added and cells were incubated in the dark at RT for 5 min. Then, 400 µl 
of 1 x Annexin V-binding buffer were added and cells were analyzed using  
FACS Calibur (BD) and FlowJo software.  
 
 
III.14.4.14 Transwell migration assay  
75000 cells were seeded in 24-well inserts (8.0 µm pore size) and placed in a 
24-well plate containing 500 µl complete cell culture medium, Wnt3a CM or 
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control CM. After 24 h migrated cells were stained with 5 µM calcein for 1 h. 
Subsequently, all cells that have not been migrated were removed and 5 
consecutive pictures at 100 fold magnification were taken for each well. Cell 
number was counted using FIJI software. 
 
 
III.14.4.15 Ca2+-flux assay  
For measuring the intracellular levels of Ca2+, 5x106 cells were incubated in 
700 µL RPMI 1640 medium supplemented with 5 % FCS, 1 mM Indo-1-AM 
(Thermo Fisher Scientific), and 0.015 % Pluronic F127 (Thermo Fisher 
Scientific) at 30°C for 25 min. The cell suspension was diluted with 700 µL 
RPMI 1640 containing 10 % FCS and incubated for additional 10 min at 
37°C. Subsequently, cells were washed twice with 600 µL Krebs Ringer 
solution. Prior to measurements cells were resuspended in 600 µL Ca2+-free 
Krebs Ringer solution supplemented with 0.5 mM EGTA. Flow cytometric 
analysis was performed on an LSR II cytometer configured with a 488 nm 
and a 355 nm laser (BD Biosciences). After monitoring the basal Ca2+ level 
for 30 s, cells were stimulated with 1 µl ionomycin. The emission 
fluorescence intensities of Indo-1-AM were recorded at wavelengths of 405 
nm and 530 nm to determine changes in the ratios of Ca2+-unbound versus 
Ca2+-bound Indo-1-AM. Data acquisition and analysis was performed with BD 




III.14.5 Western blot (WB) 
III.14.5.1 Isolation of proteins from cell culture  
Cells were harvested in 1 ml PBS using a cell scraper. Afterwards, cells were 
centrifuged for 5 min at 1000 x g and 4°C. The pellet was resuspended in 
700 µl PBS, centrifuged for 5 min at 1000 x g and 4°C and immediately 
shock-frozen in liquid nitrogen for cell lysis. Subsequently, the pellet was 
thawed on ice and resuspended in 50 µl of modified RIPA buffer. After 30 
min the lysate was centrifuged at 16000 x g and 4°C for 25 min. The 
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supernatant containing the proteins was stored at -80°C and the protein 




III.14.5.2 Isolation of proteins from tissue sample s 
30mg of tissue was cut with scalpel and added to 300µl modified RIPA buffer 
containing protease inhibitors in a 2 ml reaction tube. Subsequently, the 
tissue was homogenized for 1 min at level B of homogenizer. Afterwards, 
homogenate was shock frozen in liquid nitrogen to disrupt cell membranes, 
thawed on ice and centrifuged at 10.000 x g for 10 min at 4°C. Subsequently, 
the supernatant was transferred in a new 1.5 ml reaction tube and the protein 
concentration was measured. 
 
 
III.14.5.3 Western blot  
For sample preparation 1 x sample buffer was added to 35 µg protein lysate 
and samples were filled up to equal volumes with lysis buffer. Proteins were 
denatured for 5 min at 96°C and 450 rpm on a heating block. Proteins were 
separated using NuPAGE Novex Midi Gels in 1 x running buffer (NuPAGE 
MES SDS buffer, 20 x) for 1.5-2 h at 160 mA. For the determination of the 
molecular weight 4 µl SeeBlue Plus2 Prestained Standard were run in 
parallel. Proteins were transferred to a nitrocellulose membrane (GE 
Healthcare) using a semi-dry blotting device at 120 mA per gel for 80 min. 
After blocking with 5 % (w/v) milk powder/TBST for 1.5 h at RT and washing 
three times for 10 min in TBST the primary antibody (see Table 17) was 
added in a dilution of 1:1000 in 0.02 % (w/v) sodium azide/3 % (w/v) BSA in 
TBST. The membrane was incubated overnight on an orbital shaker at 4°C. 
Subsequently, the membrane was washed 3 x 10 min in TBST and the 
secondary antibody 1:5000 in 5 % (w/v) milk powder/TBST was added for 1 h 
at RT on orbital shaker. After three washing steps in TBST 1.5 ml the 
detection reagent (Amersham ECL Plus Western Blotting Detection 
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Reagents) per membrane was added for 3 min. For visualization the 
FluorchemQ device and AlphaView Software was used. 
 
 
III.14.6 Animal experiments 
III.14.6.1 Mouse keeping  
All used mouse lines were kept within the institutes` own mouse facility at 
12 h day-night-rhythm at 20±2°C and 50±10% humidity. Mice had ad libitum 
access to pelleted dry food and tap water. All experiments were performed in 
compliance with all relevant legal and ethical requirements. Immune deficient 
nude mice were kept in individually ventilated and sealed cages supplying ad 
libitum autoclaved pelletized dry food and tap water. 
 
 
III.14.6.2 Genotyping PCR  
Ear marks to identify each mouse and tail tip biopsies at the age of 3 weeks 
were performed by animal caretakers. Biopsies were digested using 
0.5 mg/ml proteinase K in 400 µl STE buffer over night at 56°C followed by 
ethanol precipitation to isolate genomic DNA (gDNA). 1 µl of gDNA was used 
as template for genotyping PCR utilizing appropriate DNA-oligonucleotides 
listed in Table 14. 
 
 
III.14.6.3 Intramuscular tamoxifen injection  
Tamoxifen (Sigma-Aldrich Chemie GmbH, Steinheim) was solved in 96% 
ethanol to obtain a 100mg/ml tamoxifen solution which was diluted 1:10 in 
sterile sun flower oil (Sigma-Aldrich Chemie GmbH, Steinheim). This 
emulsion (10mg/ml) was stored at -20°C. For inducing the activity of 
Cre-recombinase in the mouse lines Ptchflox/floxCreERT2T/-Wif1-/-, 
Ptchflox/floxWif1-/- and Ptchflox/floxCreERT2T/- 10µl of the tamoxifen emulsion 
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was injected in the musculus soleus of 8 week old mice using BD microfine + 
Demi syringes (Zibat et al. 2009). 
 
 
III.14.6.4 BCC mouse model and Wif1 knockout  
The analysis of BCC development was conducted using 
Ptchflox/floxROSA26-CreERT2T/- mouse model (hereafter     
Ptchflox/floxCreERT2T/-). In these mice tamoxifen injection can trigger the 
nuclear translocation of the ubiquitously expressed fusion protein consisting 
of a Cre-recombinase domain and a mutated estrogen receptor domain 
(CreERT2). Subsequently, nuclear CreERT2 can cause deletions at floxed 
sequences of host DNA. 
To analyze the effect of Wif1 on BCC formation, development and regression 
Ptchflox/flox mice were crossed to Wif1-/- mice (see Table 9). The resulting 
Ptchflox/+Wif1+/- were mated with to mice of the same gentype to generate 
Ptchflox/floxWif1-/- mice. These mice in turn were crossed with 
Ptchflox/floxCreERT2T/- mice. 
Resulting Ptchflox/floxCreERT2T/-Wif1+/- and Ptchflox/floxWif1+/- were mated to 
generate Ptchflox/floxCreERT2T/-Wif1-/-, Ptchflox/floxWif1-/- and 
Ptchflox/floxCreERT2T/- which were injected with a single dose of 100 µl 
tamoxifen emulsion (10 mg/ml, Sigma-Aldrich Chemie GmbH, Steinheim) i.m. 
at an age of 8 weeks. For the genotypes Ptchflox/floxCreERT2T/-Wif1-/- and 
Ptchflox/floxCreERT2T/- 20 animals were injected with tamoxifen. After 45 days 
and 90 days 10 animals each were euthanized for further analyses. For the 
genotype Ptchflox/floxWif1-/- 10 animals were injected with tamoxifen. After 45 
days and 90 days 5 animals each were euthanized for further analyses. 
 
 
III.14.6.5 Allograft  
Cells were suspended in a 200 µl solution of 50% matrigel in complete cell 
culture medium without puromycin. Cell suspension was subsequently 
injected subcutaneously into the flanks of nude mice using 1 ml Sub-Q 
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syringes (BD) which were precooled on ice to prevent hardening of the 
matrigel. Each nude mouse was injected bilaterally on one flank with 
ASZ-pMSCV cell suspension and on the other flank with ASZ-Wif1 cell 
suspension to exclude mouse effects. After 2 weeks when the tumors 
reached a diameter of 5mm the width (b) and length (a) of each tumor was 
measured by caliper 3 times a week and tumor volume (V) was calculation by 
use of the modified ellipsoid formula: V =	 			a·b2 (Euhus et al. 1986; Tomayko 
and Reynolds 1989). 
When the tumors reached a maximal diameter of 20 mm mice were 
euthanized and tumors were removed, weighed and measured. For RNA and 
protein isolation (see III.14.1.4 and III.14.6.2) portions of the tumors were 
snap-frozen on dry ice and for antibody stainings tumor portions were fixed in 
4% PFA for 1 week in embedding cassettes. 
 
 
III.14.7 Histological stainings 
For all histological stainings, PFA-preserved tissue was embedded in 
paraffin, cut into 5µm sections and mounted onto glass slides. All samples 
were examined by a pathologist. 
 
 
III.14.7.1 Hematoxylin and eosin (H&E) staining  
Sections were deparaffinized with xylene for 20 min and subsequently 
rehydrated using descending ethanol solutions. After washing with ddH2O, 
slides were placed in hematoxylin solution for 15 min. The staining reaction 
was done in warm tap water for at least 5 min. Samples were then quickly 
dipped in 1% eosin solution containing 0.5% (v/v) glacial acetic acid. 
Subsequently, slides were washed with ddH2O and dehydrated using 
ascending ethanol solutions. Slides were placed again in xylene and 
afterwards mounted in Pertex. Then, slides were dried at 55°C for 15 min. 
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III.14.7.2 Immunohistochemistry (IHC) 
Sections were deparaffinized with xylene and rehydrated in descending 
ethanol series. Whenever necessary, antigen retrieval was done performed 
according to Table 16. Sections were blocked with 3% H2O2 to inhibit 
endogenous peroxidases and blocked with 0.2% casein to prevent non-
specific antibody binding. Afterwards, the sections were incubated with a 
primary antibody over night at 4°C and on the next day with the appropriate 
secondary antibody (see Table 16 and Table 18) in a humid chamber. 
Antibody binding was visualized using DAB+ (Envision+ system-HRP, Dako) 
or aminoethylcarbazol as chromogen. To stop the reaction, slides were 
rinsed with distilled water. All sections were counterstained with hematoxylin. 
 
 
III.14.7.3 TdT-mediated dUTP-biotin nick end labeli ng 
(TUNEL)  
Tissue sections were deparaffinized with xylene and rehydrated with 
descending ethanol series. Afterwards, slides were first washed in 0.85% 
NaCl and then in 1 x PBS. Subsequently, slides were fixated in 4% PFA for 
15 minutes at RT and washed twice in 1 x PBS. Then, 20µg/ml proteinase K 
solution was applied on each tissue section and incubated for 10 minutes at 
RT. Afterwards, slides were washed with 1 x PBS. Tissue sections which 
were treated with a solution of 10 unit/ml RQ1 RNase-free DNase I in DNase 
I buffer served as positive controls. Then, sections were again fixated in 4% 
PFA for 5 min at RT and washed twice in 1x PBS. The labeling reaction was 
performed using the DeadEnd Colorimetric TUNEL System (Promega) 
according to the manufacturer`s protocol. Subsequently, sections were 
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III.14.7.4 Ladewig staining 
To stain for extra cellular matrix Ladewig staining was performed by the 
technical assistants in the department of neuropathology following standard 
protocols. Analysis was performed by means of FIJI software. 




IV.1  WIF1 expression in human BCC  
The relevance of WIF1 in human BCC was first tested by protein expression 
analysis of WIF1 on paraffin sections derived from 10 human BCC samples. 
As shown in Fig. 8 all analyzed human BCC samples showed WIF1 
expression (10/10). In all samples WIF1 was homogeneously expressed by 
tumor cells (see Fig. 8, arrow head). It also was expressed by tumor-
associated inflammatory cells (see Fig. 8, asterisk). Moreover, WIF1 
expression in fibrobalsts of the tumor stroma was detectable (see Fig. 8, 
arrows). Together, these data show that WIF1 is highly expressed in BCC. 
Basically all tumor cells express this protein. WIF1 is also expressed in the 

















Fig. 8: Antibody staining of WIF1 in human BCC   
Four representative stainings of paraffin sections derived from human BCC using an anti-WIF1 antibody. Staining 
reaction was performed using AEC. WIF1 expression is detectable in cells of inflammatory infiltrate (asterisk), tumor 
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As WIF1 is a well-known tumor suppressor we hypothesized that WIF1 
expression might be absent or reduced in more aggressive skin tumors such 
as SCC and melanoma. In addition, we wanted to know whether there is any 
difference in WIF1 expression in subtypes of BCC. To test this, tumor tissue 
was separated from stromal cells by laser microdissection and WIF1 
expression was analyzed in the tumor tissue by means of qRT-PCR. The 
analysis included 3 superficial, 3 nodular and 3 infiltrative BCC, 3 SCC and 3 
melanomas. WIF1 was detectable in all samples (see Fig. 9). The weakest 
expression levels were detectable in superficial and nodular subtypes of 
BCC, the highest in infiltrative BCC, SCC and melanomas. No significant 
differences between infiltrative BCC, SCC and melanomas were noticeable. 
Moreover, the differences between BCC subtypes were also not statistically 
significant. However, superficial and nodular BCC expressed significantly 
lower levels of WIF1 in comparison with SCC and melanomas. 





Fig. 9: Evaluation of WIF1 qRT-PCR of microdissected BCC subtypes, SCC and me lanomas 
3 skin samples each were analyzed. Tumor tissue was excised using laser microdissection. All data are represented 
as mean + SEM. Statistical significance was tested using unpaired t test with Welch`s correction. * p<0.05, 
*** p<0.001. 
 
Because these results seemed to be contradictory to the reported tumor 
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IV.2  Generation of a Wif1 expression vector 
IV.2.1 Cloning strategy  
According to CCDS database only one protein-coding Wif1 transcript is 
known. However, Ensemble database describes two distinct transcripts. 
These are a 1140 bp transcript encoding for a 379 aa protein (see Fig. 10) 
and a transcript variant of 1098 bp length encoding for a 365 aa protein 
lacking roughly the second half of exon 8. Nevertheless, all investigations, at 
least to our knowledge, focused on the first one. To analyze the role of Wif1 
in BCC formation and development we therefore also focused on this 
isoform. 
 
Fig. 10: Functional structure Wif1 
Wif1 consists of a 28 amino acids long N-terminal secretion signal sequence which is cleaved off upon secretion, 
the WIF domain (WD, 143 amino acid residues), five EGF-like domains (31–33 residues each) and a hydrophilic 
C-terminus.  
 
During my master thesis I cloned a Wif1 expression vector (pcDNA3-mWif1) 
containing the complete coding sequence of murine Wif1 together with a 
Kozak consensus sequence. However, as the BCC cell line ASZ001 is hard 
to transfect, the overexpression of Wif1 by means of conventional 
transfection of pcDNA3-mWif1 was unsuccessful. Therefore, the insert was 
subcloned into pMSCVpuro to generate the retroviral expression vector 
pMSCV-Wif1 as described in III.14.3.5.  




Fig. 11: Schematic of pMSCV-Wif1 
Retroviral expression vector containing murine Wif1 ORF. BglII(0), BamHI(1131), HpaI(1170), HindIII(1696): 
restriction sites for respective endonucleases. Puror: puromycin resistance cassette for stable selection in eukaryotic 
expression systems. Ampr: Ampicillin resistance cassette for selection in prokaryotic expression systems. 3` and 
5`LTR: 3` and 5` long terminal repeats, sequences allowing for stable integration into target cell genome. Ψ+: 
packaging signal for retrovirus production in Platinum-E packaging cell line. PPGK: promoter for puromycin 
expression in eukaryotic cells. Col E1 ori: origin of replication. 
 
The correct orientation of the insert was assessed by restriction hydrolysis 
and sequencing. As described in III.14.4.8 the supernatants from Platinum-E 
cells with retroviral particles containing pMSCV (control) or pMSCV-Wif1, 
respectively, were used for transduction of ASZ001. 
 
 
IV.2.2 Selection of stably transfected cells and 
verification of Wif1 expression 
2 days after transduction of ASZ001 with either pMSCV control vector or the 
pMSCV-Wif1 overexpression plasmid, cells were treated with 2 µg/ml 
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were isolated by limited dilution. RNA was isolated, reversely transcribed and 





Fig. 12: PCR detecting Wif1 of pMSCV and pMSCV-Wif1 transduced ASZ001 cells  
PCR product of 220 bp length was generated as expected. 
 
Moreover, in order to confirm the translation of the Wif1 mRNA a Western 







Fig. 13: Western blot detecting Wif1 of pMSCV and pMSCV-Wif1 transduced ASZ001 cells 
Antibody detecting Hsc70 served as loading control.  Single cell clones and a polyclonal cell populatio n (no 
single cell clone selection) were analyzed regardin g Wif1 expression. 
 
As shown in Fig. 13 protein samples from pMSCV transduced ASZ001 cells 
(hereafter ASZ-pMSCV) do not express detectable levels of Wif1. In contrast, 
in the samples isolated from pMSCV-Wif1 transduced ASZ001 cells 
(hereafter ASZ-Wif1) the Wif1 protein was detected at the expected size of 
42 kDa. This confirmed the successful transduction and operability of the 
retroviral expression plasmid pMSCV-Wif1 to induce Wif1 overexpression.  
For the analysis of successful Wif1 production and secretion the supernatant 
of ASZ-Wif1 was 75-fold concentrated (see III.14.4.5) and analyzed by 
Western blot. As shown in Fig. 14, Wif1 is not only expressed by ASZ-Wif1 

















Fig. 14: Western blot detecting Wif1 in supernatant  and cellular extracts of ASZ -pMSCV and ASZ- Wif1 




IV.3 Functional analysis of Wif1 in vitro 
Wif1 is a well-known inhibitor of Wnt signaling due to sequestration of Wnt 
ligands in the extra cellular space. Orthologs of human WIF1 have also been 
shown to interact with Hh thereby promoting its activity. In addition, the Wnt 
and Hh signaling pathways can influence each other at several interfaces. To 
investigate whether Wif1 can modulate the activity of the latter signaling 
cascades, I employed functional assays and analyzed target gene 
expression of the respective pathways. To analyze the function of Wif1 in 
vitro on Wnt and Hh signaling, I analysed the expression of Axin2 and Gli1, 
respectively. I also tried to establish the TOP/FOP reporter assay, which is 
useful to analyze the activity of the Wnt signaling pathway after its induction 
with Wnt ligands.  
 
 
IV.3.1 TOP/FOP reporter assay for assessment of Wif1 
activity 
In order to analyze the inhibitory capability of Wif1 on Wnt ligands and thus 
on Wnt signaling activity, the TOP/FOP reporter assay was used as 
described in III.14.4.9.  
As mentioned above ASZ001 are hard to transfect using lipid based 
transfection systems. However, nucleofection improved the plasmid transfer 
in ASZ001 resulting in ~50 % eGFP positive cells when using the reporter 
Wif1 (42 kDa) 
Hsc70 (70 kDa) 
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plasmid pGFPmax (data not shown). Unfortunately, this method significantly 
reduced ASZ001 cell viability (data not shown).  
Nevertheless, ASZ001 were transfected with the TOP plasmid. 
Cotransfection with pCl-neo-β-cateninS33Y encoding for a mutationally, 
constitutively activated β-catenin (S33Y) served as positive control. TOP 
transfected cells were incubated with Wnt3a conditioned medium derived 
from stably transfected L cells (Wnt3a CM). Conditioned medium from 
untransfected L cells (L CM) served as control medium. As negative control, 
ASZ001 were transfected with the FOP and S33Y plasmids (data not shown). 
 
Fig. 15: TOP/FOP reporter assay of Wnt signaling in ASZ001 cells in cubated with Wnt3a  
As positive control ASZ001 cells were co-nucleofected with SuperTOPFlash (TOP) and pCl-neo-β-cateninS33Y 
(S33Y). As negative control ASZ001 were co-nucleofected with SuperFOPFlash (FOP) and S33Y. ASZ001 cells 
only nucleofected with TOP or TOP transfected cells incubated with conditioned medium of untransfected L cells (L 
CM) were used as further controls. In addition, TOP nucleofected cells were incubated with Wnt3a conditioned 
medium from L cells stably expressing and secreting Wnt3a in order to activate canonical Wnt signaling driving 
luciferase expression (Wnt3a CM). Firefly luciferase activity was normalized to Renilla luciferase activity, which is 
under CMV promoter control. All data are represented as mean + SEM. Statistical significance was tested using 
Mann-Whitney U test. rlu: relative light units. 
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However, neither the positive control TOP + S33Y nor Wnt3a CM did induce 
luciferase activity in this assay. Therefore, we decided to change the 
experimental setup and employed the easy-to-transfect cell line HEK-293 for 
further experiments. For activation of Wnt signaling Wnt3a CM was used. 
The 75-fold concentrated supernatant of ASZ-Wif1 cells (Wif1 conc. SN, see 
Fig. 16) was employed and 75-fold concentrated supernatant of ASZ-pMSCV 
(pMSCV conc. SN) served as control. As additional controls of successful 
Wnt signaling inhibition, I used recombinant dickkopf1 (rDkk1) at a 
concentration of 750 ng/ml and recombinant Wif1 (rWif1) protein at a 
concentration of 30 µg/ml. In HEK-293 cells, all negative controls (i.e. TOP, 
FOP or FOP + S33Y) did not induce luciferase activity. In contrast, 
transfection with TOP + S33Y highly induced luciferase activity. Cells that 
were transfected with TOP in combination with a 24 h incubation with a 1:1 
mixture of Wnt3a CM and pMSCV conc. SN moderately induced luciferase 
activity (24 h incubation with Wnt3a CM alone resulted in an equal induction 
of luciferase activity, data not shown). This induction was significantly 
reduced by Wif1 conc. SN comparable with 30 µg/ml rWif1 and to a lesser 








Fig. 16: TOP/FOP reporter assay in HEK-293 cells incubated with Wnt 3a and Wif1-concentrated supernatant 
As positive control HEK-293 cells were co-nucleofected with SuperTOPFlash (TOP) and pCl-neo-β-cateninS33Y 
(β-cat S33Y). As negative control HEK-293 were co-nucleofected with SuperFOPFlash (FOP) and S33Y. HEK-293 
cells only nucleofected with TOP or TOP transfected cells incubated with conditioned medium of untransfected L 
cells (L CM) were used as further controls. In addition, TOP nucleofected cells were incubated with Wnt3a 
conditioned medium from L cells stably expressing and secreting Wnt3a in order to activate canonical Wnt signaling 
driving luciferase expression (Wnt3a CM). Moreover, cells were incubated with concentrated supernatant from 
ASZ-pMSCV (pMSCV SN) and from ASZ-Wif1 (Wif1 SN), respectively. Firefly luciferase activity was normalized to 
Renilla luciferase activity, which is under CMV promoter control. As a control for efficient Wnt inhibition recombinant 
dickkopf1 protein (rDkk1) (750 ng/ml) and recombinant Wif1 protein (rWif1) (30 µg/ml) were used. Firefly luciferase 
activity was normalized to Renilla luciferase activity. rlu: relative light units. All data are represented as mean + 
SEM. Statistical significance was tested using Mann-Whitney U test. * p< 0.05, ** p< 0.005, *** p< 0.001.  
 
Together, these data demonstrate that ASZ-Wif1 cells express and secrete 
functionally active Wif1. 
 
 
IV.3.2  Analysis of Hh and Wnt pathway activity and  
Ca2+ measurement 
Axin2 and Gli1 are considered as the most general and common target 
genes of active Wnt and Hh signaling, respectively. Analysis of ASZ-pMSCV 
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and ASZ-Wif1 by means of qRT-PCRs showed no significant differences in 
expression levels of both genes (see Fig. 17).  
     
Fig. 17: qRT-PCR of Axin2 and Gli1 in ASZ- pMSCV and -Wif1 
Relative Axin2 and Gli1 expression in ASZ-pMSCV and -Wif1. Values were normalized to Hprt expression. All data 
are represented as mean + SEM. Statistical significance was tested using Mann-Whitney U test. 
 
However, as both cell lines do not feature a priori activated Wnt signaling, it 
cannot be ruled out that Wif1 might have affected Axin2 expression in an 
activated status of Wnt signaling. Unfortunately, Wnt3a transfected L cells do 
not secrete Wnt3a when cultured in 154 CF medium that is used to 
propagate ASZ001.  Vice versa, ASZ001 differentiate in DMEM based 
medium due to high Ca2+ concentrations, biasing Wnt target gene expression 
analysis.  
Next, the cytoplasmic Ca2+ concentrations as an indicator for active Wnt/Ca2+ 
signaling were examined. In addition the Ca2+ influx from ER into the 
cytoplasm was analyzed by Ca2+-influx assay (see Fig. 18). 
 




Fig. 18: Ca 2+-influx assay of ASZ- pMSCV and -Wif1  
Ratio of bound and free indo-1 AM was measured for 60 s to determine the basal Ca2+ levels (top). After 60 s 
1 µg/ml ionomycin was added (arrow) to establish a maximum Calcium flux ratio for each cell line (bottom). 
 
However, neither the basal cytoplasmic Ca2+ concentrations nor the 
maximum Ca2+ flux ratio was altered in ASZ-Wif1 compared to ASZ-pMSCV. 
 
 
IV.4  Effect of Wif1 overexpression on various 
cellular processes of ASZ001 in vitro  
Wif1 has been implicated in various cellular processes including the 
regulation of cell viability, apoptosis, migration, epithelial-to-mesenchymal 
transition (EMT), differentiation, cell cycle progression and proliferation. The 
impact of Wif1 on these processes was analyzed in vitro in ASZ-Wif1 and 
ASZ-pMSCV control cells. 
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IV.4.1 Effect of Wif1 on cell viability in vitro 
Cell viability was analyzed by WST-1 assay. 5.000 cells/well were seeded in 
96-well plates and cultured for 48 h in total.  Incubation for the last 24 h with 
200 mM H2O2 served as a control for reduced cell viability. WST-1 assay was 
performed 3 times in triplicates. As expected, incubation with 200 mM H2O2 
significantly reduced cell viability compared to untreated cells. However, no 
significant difference between the cell lines were detected, neither after 
incubation with H2O2 nor between untreated ASZ-pMSCV and ASZ-Wif1 cells 
(see Fig. 19; shown is a representative experiment). 
 
Fig. 19: WST-1 assay of ASZ- pMSCV and –Wif1 
ASZ-pMSCV and –Wif1 cells were cultured untreated in 154 CF supplemented with 2 % chelexed FCS and 1 % P/S 
for 48 h in total or treated for the last 24 h with 200 mM H2O2 (H2O2). All data are represented as mean + SEM. 
[a. u.]: arbitrary units. Statistical significance was tested using Mann-Whitney U test. 
 
 
IV.4.2 Effect of Wif1 on apoptosis in vitro 
In order to investigate the effect of Wif1 on apoptosis in vitro we used an 
Annexin V assay as described in III.14.4.13. Shown is a representative 
experiment performed in duplicates. As a positive control 1 µM of the protein 
kinase inhibitor staurosporine (stauro) was applied for 24 h. Staurosporine 
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significantly induced apoptosis in both cell lines. However, no significant 
difference between ASZ-pMSCV and ASZ-Wif1 cell lines was detected. The 
difference was also not significant when the values of untreated ASZ-pMSCV 
and ASZ-Wif1 were compared (see Fig. 20). 
 
Fig. 20: Annexin V assay of uninduced and staurospo rine induced ASZ- pMSCV and –Wif1 
Annexin V negative, propidium iodide (PI) positive cells were considered as necrotic (not shown). Annexin V 
negative, propidium iodide (PI) negative cells were considered as living cells (not shown). Annexin V positive cells 
were considered as apoptotic. Cells were treated either with DMSO or 1 µM staurosporine (stauro) for 24 h. 
Respective proportion of cells that are apoptotic is given in percent. All data are represented as mean + SEM. 
Statistical significance was tested using Mann-Whitney U test. 
 
 
IV.4.3 Effect of Wif1 on cell cycle regulation and 
proliferation in vitro 
To analyze the effect of Wif1 on cell cycle regulation a PI staining was 
performed. Compared to ASZ-pMSCV the cell line ASZ-Wif1 showed a 
tendency to accumulate in the G1 phase of the cell cycle. This resulted in a 
reduced proportion of cells in the G2/M phase (see Fig. 21), which, however, 
was statistically not significant.  



























Fig. 21: Distribution of ASZ- pMSCV and –Wif1 in respective phases of cell cycle 
All values represent the mean + SEM of 2 independent experiments performed in duplicates in G0/G1, S and G2/M 
phase of cell cycle. Statistical significance was tested using Wilcoxon test. 
 
In order to investigate whether the accumulation of the cells in G1 was 
associated with changes in DNA replication, a BrdU assay was performed. 
The cells were cultured for 72 h and labelled with BrdU for the last 24 h. The 
analysis was conducted 3 times in sextuplicates. Shown is a representative 
experiment (see Fig. 22). However, there was no significant difference in 
cellular proliferation when comparing the values for ASZ-pMSCV and 
ASZ-Wif1.  
 




Fig. 22: BrdU assay of ASZ- pMSCV and –Wif1 
ASZ-pMSCV and –Wif1 cells were cultured untreated in regular culture medium for 72 h. BrdU was added for the 
last 24 h. All data are represented as mean + SEM. Statistical significance was tested using unpaired t test with 
Welch`s correction. 
 
Moreover, ASZ-pMSCV and ASZ-Wif1 cells were cocultivated with Wnt3A L 
and L cells, with Wnt5a-NIH/3T3 and NIH/3T3 cells, with B9 (murine 
fibroblasts) and murine bone marrow derived macrophages (BMDMs). This 
allowed for examination of potential effects of Wif1 on cellular proliferation in 
response to cues derived from adjacent fibroblasts or macrophages. For this 
purpose, ASZ-pMSCV and ASZ-Wif1 were seeded in a 24-well plate. On the 
same day, the cell lines used for coculture were seeded in 24-well plate 
inserts and the inserts were placed in the 24-well plate. On each day of 5 
consecutive days the cell numbers were counted using the CeligoS device 





































Fig. 23: Cell proliferation assay of ASZ- pMSCV and ASZ– Wif1 cocultured with B9, L cells, Wnt3A L cells, 
NIH/3T3, Wnt5a-NIH/3T3 or BMDMs 
ASZ-pMSCV, ASZ-Wif1 and cocultured cells were seeded on day 0 in 24-well plates or 24-well plates inserts, 
respectively. Cells were counted each day of 5 consecutive days. All data are represented as mean ± SEM.  
 
ASZ-pMSCV and ASZ-Wif1 cells showed an exponential growth and reached 
the plateau phase between day 4 and day 5. This was seen in all settings. 
- 




Wnt3A L cells  
B9 
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None of the cocultured cells elevated or decreased the proliferation of 
ASZ-Wif1 when compared to ASZ-pMSCV. 
In summary, these data suggest that Wif1 does not alter the proliferative 
capacity of ASZ001 in vitro. 
 
 
IV.4.4 Effect of Wif1 on migration in vitro 
As Wif1 has also been shown to inhibit migration of several cancer cell lines 
(Yee et al. 2010; Vassallo et al. 2015), the migratory capacity of ASZ-pMSCV 
and ASZ-Wif1 was investigated in a transwell migration assay (see Fig. 24). 
However, the migratory capacity of ASZ-Wif1 cells did not show any 
significant difference compared to ASZ-pMSCV cells. 
 
Fig. 24: Transwell migration assay of ASZ- pMSCV and –Wif1 
Cells were seeded in 24-well plate inserts. 16 h later cells that had migrated through 8.0 µm pores were counted. All 
data are represented as mean + SEM. Statistical significance was tested using Wilcoxon test. 
 
IV.4.5 Effect of Wif1 on differentiation in vitro 
The cellular morphology of ASZ-Wif1 and ASZ-pMSCV cells was examined 
microscopically. No obvious alterations in cell morphology were observed. 
Next, the expression of the differentiation markers Krt1 and Krt10 were 
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analyzed by means of qRT-PCR. Krt1 was not expressed and Krt10 
expression was not changed significantly in ASZ-Wif1 compared to 
ASZ-pMSCV. 
 
Fig. 25: qRT-PCR of Krt10 in ASZ- pMSCV and -Wif1 
Relative Krt10 expression in ASZ-pMSCV and -Wif1. Values were normalized to Hprt expression. All data are 
represented as mean + SEM. Statistical significance was tested using Mann-Whitney U test.  
 
 
IV.5 Effect of Wif1 in vivo 
In order to investigate the influence of Wif1 on BCC growth in mice, 1·106 
cells of both cell lines suspended in matrigel were subcutaneously 
transplanted in the flanks of nude mice. In order to exclude individual mouse 
effects, each mouse was injected with 200 µl of ASZ-pMSCV and ASZ-Wif1 
cell suspension in matrigel on the left and right flank, respectively. When 
reaching a size of 5 mm, tumor size was measured every second day using a 
caliper. Measurement was conducted until general health conditions or tumor 
size required the termination of the experiment. The age of the 17 mice upon 
transplantation was 10 weeks.  
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As demonstrated in Fig. 26, the minimum size of the tumors (i.e. 5 mm) was 
generally reached at day 17 after transplantation. Then the tumors showed 
an approximately exponential growth until day 33 after injection. Tumors that 
arose from transplanted ASZ-pMSCV cells grew significantly faster compared 
to tumors that originated from ASZ-Wif1 cells (see Fig. 26). Indeed, the size 
of ASZ-pMSCV-derived tumors was significantly larger at any time point 
during measurement. 
 
Fig. 26: Growth curve of ASZ -pMSCV and ASZ- Wif1 allografts in nude mice 
1·106 cells in a 200 µl cell suspensions in matrigel of either ASZ-pMSCV or ASZ-Wif1 were injected in the left or 
right flank, respectively, in 17 nude mice. After the tumors reached a minimum diameter of 5 mm the tumor size 
were measured every other day. All data are represented as mean ± SEM. Statistical significance was tested using 
Wilcoxon test. ** p< 0.005, *** p< 0.001. 
 
The significant difference in tumor sizes was also reflected by a significantly 
reduced tumor weight of tumors originating from transplanted ASZ-Wif1 cells. 
(see Fig. 27).  




Fig. 27: Tumor weight of ASZ -pMSCV and ASZ- Wif1 allografts after dissection 
1·106 cells in a 200 µl cell suspensions in matrigel of either ASZ-pMSCV or ASZ-Wif1 were injected in the left or 
right flank, respectively, in 17 nude mice. After the termination of the experiment, tumors were removed and 
weighed. All data are represented as a box-whisker plot: median (horizontal line), 25-75 percentile (box), 5-95 
percentile (whiskers). Statistical significance was tested using Wilcoxon test.  ** p< 0.005. 
 
Similar results were obtained when 1·106 cells originating from 3 different 
single cell clones of both cell lines (see section IV.2.2 and Fig. 13) were 
transplanted (data not shown). 
In Fig. 28 representative images of H&E stainings of ASZ-pMSCV and 
ASZ-Wif1 derived allografts are depicted. Both groups of allografts show 
growth of tumor nodules surrounded by stroma, spots of differentiation in 
form of keratinization (arrows) and areas of necrosis (asterisks) (see Fig. 28). 
IV      Results 
82 
 
Fig. 28: H&E stainings of ASZ -pMSCV and ASZ- Wif1 allografts 
Arrows indicate spots of keratinization. Asterisks indicate necrotic areas. 
 
In order to rule out that the difference in tumor size between ASZ-pMSCV 
and ASZ-Wif1 derived tumors was not simply caused by swelling of 
ASZ-pMSCV allografts due to increased keratinization and necrosis, the 
areas which were clearly necrotic or keratinous were subtracted from the 
total tumor area. This was done on serial images using the software 
cellSens. Fig. 29 shows two examples of the total tumor (overlay of serial 
images). The red lines indicate the borders of vital tumor tissue and necrotic/ 
keratinous areas. 
 
Fig. 29: Total sections of ASZ- pMSCV and ASZ- Wif1 allografts  
Necrotic and keratinous areas were encircled and separated from the total tumor areas by red lines. Image 
acquisition, image overlay and area demarcation were performed using cellSens software.  
 
The proportion of necrotic and keratinous areas in ASZ-pMSCV allografts 
was moderately decreased compared to ASZ-Wif1 allografts. However, this 
difference was statistically not significant (see Fig. 30). 
* 
* 




Fig. 30: Vital tumor area of ASZ- pMSCV and ASZ- Wif1 allografts  
Necrotic and keratinous areas were measured and subtracted from total tumor area of 7 different ASZ-pMSCV and 
ASZ-Wif1 derived tumors. Image acquisition and area calculation was performed using cellSens software. All data 
are represented as a box-whisker plot: median (horizontal line), 25-75 percentile (box), 5-95 percentile (whiskers). 
Statistical significance was tested using Wilcoxon test. 
 
 
IV.5.1 Effect of Wif1 on Hh, Wnt and Akt signaling 
pathways in vivo 
In order to analyze the effect of Wif1 overexpression on Wnt and Hh 
signaling, target gene expression analysis of both pathways was performed. 
Ten tumor samples from each group (i.e. ASZ-pMSCV and ASZ-Wif1 derived 
tumors) were analyzed.  
When the Hh target Gli1 was measured, the tumors did not show different 
levels of Gli1 expression indicating comparable Hh signaling activity in 
ASZ-pMSCV and ASZ-Wif1 allografts (see Fig. 31). 




Fig. 31: qRT-PCR of Gli1, Axin2 and c-Myc expression in ASZ -pMSCV and ASZ- Wif1 allografts 
Each bar summarizes data of 10 individual ASZ-pMSCV or ASZ-Wif1 derived tumors. Values were normalized to 
Hprt expression. Statistical significance was tested using Wilcoxon test. All data are represented as a box-whisker 
plot: median (horizontal line), 25-75 percentile (box), 5-95 percentile (whiskers). Statistical significance was tested 
using Wilcoxon test. 
 
Similarly, Wif1 overexpression did not influence the expression of c-Myc and 
Axin2. This indicates that canonical Wnt signaling was not affected (see Fig. 
31). Moreover, translocation of β-catenin into the nucleus, which is a 
hallmark of active canonical Wnt signaling, was investigated. For this 








Fig. 32: Antibody staining of β-catenin in ASZ -pMSCV and ASZ- Wif1 allografts  
Anti-ß-catenin antibody staining of paraffin sections derived from ASZ-pMSCV and ASZ-Wif1 allografts. Images 
were taken at 100-fold magnification. Intestinal crypts served as positive control for nuclear staining of β-catenin 
(arrows). Staining reaction was performed using DAB+. 
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As shown in Fig 32, Wif1 also did not affect β-catenin translocation. 
Together, absent nuclear β-catenin staining and unchanged target gene 
expressions in ASZ-pMSCV and ASZ-Wif1 derived allografts indicate that 
Wif1 does not affect canonical Wnt signaling.  
Next, the phosporylation status of JNK and CaMKII was examined, which are 
targets of the β-catenin-independent (i.e. non-canonical) Wnt/PCP and 
Wnt/Ca2+ signaling pathways, respectively. Besides allografts I also analyzed 
the phosphorylation status of the proteins in the respective parental cell lines. 
Neither JNK nor CaMKII showed significant phosporylation compared to the 
positive controls indicating that both kinases are inactive both in vitro and in 






Fig. 33: Western blot of pJNK and pCaMKII in ASZ -pMSCV and ASZ- Wif1 allografts 
Protein samples from ASZ-pMSCV and ASZ-Wif1 in vitro cultures (in vitro) and from allografts of the three mice #96, 
97 and 99 (#96, 97 and 99) were analyzed. pJNK antibody detects phosphorylated SAPK/JNK (Mapk8/9) protein 
with the size of 46 kDa and 54 kDa. pCaMKII antibody detects phosphorylated CaMKII protein with the size of 50 
kDa (data not shown) and 60 kDa. Hsc70 served as loading control. 
 
As discussed later Wif1 was described to bind several EGF receptors. For 
this reason, the phosphorylation status of several proteins involved in EGFR 
signaling was analyzed. Fig. 34 shows the phosphorylation status of Akt and 
of S6. S6 is a target of mTOR which in turn can be activated by Akt. As 
shown in Fig. 34 Akt is unphosphorylated in ASZ-pMSCV and ASZ-Wif1 in 
vitro samples. In contrast, the individual allograft samples showed elevated 
phosphorylation levels compared with in vitro samples. However, they exhibit 
a very heterogeneous protein expression and protein phosphorylation 
pattern, which was not clearly different between ASZ-pMSCV and ASZ-Wif1 
derived allografts. The same was true for the Akt/mTOR downstream target 
ASZ-pMSCV ASZ-Wif1 
Hsc70 (70 kDa) 
pJNK(46 kDa, 54 kDa) 
pCaMKII (60 kDa) 
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S6. Therefore, the data suggest that Wif1 overexpression does not 






Fig. 34: Western blot of pAkt, Akt, pS6 and S6 in A SZ-pMSCV and ASZ- Wif1 allografts 
Protein samples from ASZ-pMSCV and ASZ-Wif1 in vitro cultures (in vitro) and from allografts of the six mice #96, 
97, 99, 106, 107 and 109 (#96, 97, 99, 106, 107 and 109) were analyzed. pAkt antibody detects phosphorylated Akt 
and Akt antibody detects total Akt protein with a size of 60 kDa. pS6 antibody detects phosphorylated S6 and S6 
antibody detects total S6 protein with a size of 32 kDa. Hsc70 served as loading control. Please note that Hsc70 
loading control in this Figure is identical with that in Fig. 36 and Fig. 46 as all proteins were detected using the same 
membrane. 
 
Beside S6 and Akt, the additional downstream effectors of EGFR signaling 
PKC and Erk1/2 were examined regarding their phosphorylation status. The 
ASZ-Wif1 cell line (in vitro; see Fig. 35) showed an elevated phosphorylation 
level of PKC compared with the ASZ-pMSCV cell line. Moreover, PKC 
phosphorylation was maintained in ASZ-Wif1 derived allografts. In 
ASZ-pMSCV allografts the phosphorylation status remained at low levels 





Fig. 35: Western blot of pPKC in ASZ -pMSCV and ASZ- Wif1 
Protein samples from ASZ-pMSCV and ASZ-Wif1 in vitro cultures (in vitro) and from allografts of the four mice #95, 
96, 97 and 99 (#95, 96, 97 and 99) were analyzed. Pan pPKC antibody detects phosphorylated forms of PKC 
protein with a size of 78-82 kDa. pErk1 and 2 antibody detects phosphorylated Erk1 and 2 protein with a size of 44 
and 42 kDa, respectively. Erk1 and 2 antibody detects total Erk1 and 2 protein with a size of 44 and 42 kDa, 
respectively. Hsc70 served as loading control. 
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The total amounts of Erk1 and Erk2 were at comparable levels in all analyzed 
in vitro and in vivo samples, except for ASZ-pMSCV and ASZ-Wif1 allografts 
from mouse #109 showing relatively low total Erk1 and Erk2 expression 
levels (see Fig. 36). Moreover, the total expression of Erk2 seemed to be 
higher than total expression of Erk1 in all samples, provided that the antibody 
has equal binding affinities to both proteins. The phosphorylation of Erk2 in 
both in vitro samples was at comparable levels. In the allografts, the 
phosphorylation of Erk2 seemed to be slightly increased in most ASZ-Wif1 
derived samples (#96, 99, 106, 107 and 109) compared with ASZ-pMSCV 
allografts. Interestingly, the phosphorylation of Erk1 was slightly increased in 
the ASZ-Wif1 cell line compared to the ASZ-pMSCV cell line. When the cell 
lines were transplanted Erk1 phosphorylation was reduced in ASZ-pMSCV 





Fig. 36: Western blot of pErk1 and 2 and Erk1 and 2  in ASZ -pMSCV and ASZ- Wif1 allografts 
Protein samples from in vitro cultures and from allografts (#96-109) were analyzed. pPKC antibody detects 
phosphorylated forms of PKC protein with a size of 78-82 kDa. pErk1 and 2 antibody detects phosphorylated Erk1 
and 2 protein with a size of 44 and 42 kDa, respectively. Erk1 and 2 antibody detects total Erk1 and 2 protein with a 
size of 44 and 42 kDa, respectively. Hsc70 served as loading control. Please note that Hsc70 loading control in this 
Figure is identical with that in Fig. 34 and with that in Fig.46 as all proteins were detected using the same 
membrane. 
Together, these results suggest that Wif1 overexpression in ASZ001 cells 
results in the maintenance of PKC and Erk1/2 phosphorylation after 
transplantation in nude mice. 
 
 
IV.5.2 Cellular response on Wif1 in vivo 
As Wif1 reduced the growth of ASZ derived allografts (see Fig. 26), the 
differentiation status, apoptosis, the deposition of extracellular matrix, 
vascularization and proliferation of the tumors were analyzed. 
ASZ-pMSCV ASZ-Wif1 
Hsc70 (70 kDa) 
pErk1 (44 kDa) 
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Erk1 (44 kDa) 
Erk2 (42 kDa) 
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IV.5.2.1 Effect of Wif1 on differentiation in vivo 
The expression of early and late markers for differentiation of keratinocytes 
was analyzed by qRT-PCR and the proportion of keratin in the allografts was 
measured using the cellSens software.  
The markers for early differentiation, loricrin (Lor) and involucrin (Ivl), as well 
as the markers for late differentiation, keratin 1 and 10 (Krt1 and Krt10), did 
not show any significant differences in expression levels when the data of 10 
individual ASZ-pMSCV or ASZ-Wif1 allografts were compared (see Fig. 37). 
Fig. 37: qRT-PCRs of early and late keratinocyte di fferentiation markers in ASZ -pMSCV and ASZ- Wif1 
allografts   
Each bar summarizes data of 10 individual ASZ-pMSCV or ASZ-Wif1 derived tumors. Statistical significance was 
tested using Wilcoxon test. All data are represented as a box-whisker plot: median (horizontal line), 25-75 percentile 
(box), 5-95 percentile (whiskers). Statistical significance was tested using Wilcoxon test. 
 
In order to determine the proportion of keratin in the allografts, keratinous 
areas were subtracted from vital tumor area of H&E stained paraffin sections 
using cellSens software. For this purpose, 3 pictures each derived from either 
16 ASZ-pMSCV or 16 ASZ-Wif1 tumors were analyzed. However no 








Fig. 38:  Proportion of keratinous tissue in ASZ -pMSCV and ASZ- Wif1 allografts  
Proportion of keratin in % was measured in H&E stained paraffin sections by means of cell sense software. Each 
plot summarizes values from 3 images each derived from 16 individual tumors. Statistical significance was tested 
using Mann-Whitney U test. All data are represented as a box-whisker plot: median (horizontal line), 25-75 
percentile (box), 5-95 percentile (whiskers). Statistical significance was tested using Wilcoxon test. 
 
 
IV.5.2.2  Effect of Wif1 on EMT marker gene express ion 
in vivo  
Since Wif1 can induce a reversal of EMT in prostate cancer cells (Yee et al. 
2010), the expression of Cdh1, Cdh2 and Fn1 was analyzed by means of 
qRT-PCR. While upregulation of Cdh1 is indicative for the induction of 
epithelial cell fate, Cdh2 and Fn1 expressions are associated with EMT. 
However, as demonstrated in Fig. 39, none of the examined transcripts was 
differentially expressed in ASZ-pMSCV or ASZ-Wif1 derived allografts. 
 
 




Fig. 39: qRT-PCRs of EMT markers in ASZ -pMSCV and ASZ- Wif1 allografts  
Each plot  summarizes values from 10 individual ASZ-pMSCV and ASZ-Wif1 allografts each. Statistical significance 
was tested using Wilcoxon test. All data are represented as a box-whisker plot: median (horizontal line), 25-75 
percentile (box), minimum and maximum values (whiskers). Statistical significance was tested using Wilcoxon test. 
 
 
IV.5.2.3 Effect of Wif1 on vascularization 
Vascularization can restrict growth and size of tumors as it limits the supply 
with nutrients. To investigate whether Wif1 alters the vascularization of the 
tumors, paraffin sections were stained with an antibody against CD34, which 
is a marker for vascular endothelial cells. Counting the vessels per vision 
field revealed no significant difference between ASZ-pMSCV and ASZ-Wif1 
allografts (see Fig. 40).  
 
 




Fig. 40:  Number of CD34 positive blood vessels in ASZ -pMSCV and ASZ- Wif1 allografts   
Number of blood vessels was counted on paraffin sections stained with an anti CD34 antibody. Analyzed were 3 
images of 8 allograft samples each. Statistical significance was tested using Mann-Whitney test. All data are 
represented as a box-whisker plot: median (horizontal line), 25-75 percentile (box), minimum and maximum values 
(whiskers). Statistical significance was tested using Wilcoxon test. 
 
 
IV.5.2.4 Effect of Wif1 on cell death in vivo 
Since apoptosis could have been causative for reduced growth of ASZ-Wif1 
derived allografts, Western blot detecting cleaved Caspase 3 in protein 
lysates and TUNEL and p53 staining using paraffin sections from 
ASZ-pMSCV and ASZ-Wif1 allografts were performed. Cleavage of 
Caspase 3 and nuclear localization of p53 indicate the induction of apoptosis. 
Moreover, when cells undergo apoptosis, fragmentation of DNA occurs, 
which can be visualized by TUNEL.  
When the cleavage of Caspase 3 was analyzed, no obvious differences 
between ASZ-pMSCV and ASZ-Wif1 allografts could be detected (see Fig. 
41). Furthermore, neither the percentage of cells positive for nuclear p53 
(see Fig. 42) nor TUNEL (see Fig. 43) revealed significant differences 
between ASZ-pMSCV and ASZ-Wif1 derived allografts. 
 















Fig. 41: Western blot of Caspase 3 in ASZ -pMSCV and ASZ- Wif1 allografts  
Protein samples from in vitro cultures and from allografts (#95, 96, and 99) were analyzed. Caspase 3 antibody 
detects total Caspase 3 proenzyme protein with a size of 35 kDa and the cleaved Caspase 3 at a size of 17 and 19 
kDa. Hsc70 served as loading control. 
 
 
Fig. 42:  Nuclear p53 staining of ASZ -pMSCV and ASZ- Wif1 allografts.   
Proportion of nuclear p53 staining was calculated using the FIJI software. Analyzed were 3 images of 7 allograft 
samples each. All data are represented as a box-whisker plot: median (horizontal line), 25-75 percentile (box), 5-95 
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Fig. 43:  TUNEL staining of ASZ -pMSCV and ASZ- Wif1 allografts  
Number of positive cells staining was calculated using the Alpha View software. Analyzed were 3 images of 7 
allograft samples each. All data are represented as a box-whisker plot: median (horizontal line), 25-75 percentile 
(box), 5-95 percentile (whiskers). Statistical significance was tested using Wilcoxon test. 
 
Together, these data show that induction of apoptosis is not the mechanism 
underlying reduced tumor growth of ASZ-Wif1 allografts. 
 
 
IV.5.2.5 Effect of Wif1 on deposition of extracellu lar 
matrix in vivo 
Remodelling of extracellular matrix (ECM) is necessary for tumor cell 
migration and metastasis. However, whether ECM is protective or not is 
highly context specific and depends on the composition of ECM components 
(Honma et al. 2007; Fullar et al. 2015). To investigate whether Wif1 changes 
the global deposition of collagen which is a main component of the ECM, 
Ladewig staining of paraffin sections was performed in the Department of 
Neuropathology, University Medical Center Göttingen. This method results in 
blue coloring of collagens. Shown in Fig. 44 are examples of paraffin sections 
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from ASZ-pMSCV and ASZ-Wif1 derived allografts (top row). The collagen 
was stained in blue and after image software based extraction of the blue 
channel a black and white image was generated (bottom row) allowing for 
automated quantification of the collagen proportion using FIJI software (see 
Fig. 44).  
 
Fig. 44:  Ladewig staining of ASZ -pMSCV and ASZ- Wif1 allografts  
Ladewig staining of paraffin sections of ASZ-pMSCV and ASZ-Wif1 allografts was performed according to standard 
protocols. Collagens are stained in blue (top row). Using image software FIJI the blue channel was extracted and a 
black and white image was generated (bottom row).  
 
Since the tumors also contained necrotic areas (see Fig. 28), the proportion 
of collagen within the vital as well as in the necrotic tumor tissue was 
calculated. Shown in Fig. 45 is the mean proportion of collagen per vision 
field and the 95% confidence interval (CI). In both, the viable tumor areas 
and necrotic areas, ASZ-Wif1 derived allografts exhibited an increased 









Fig. 45:  Collagen proportion in ASZ -pMSCV and ASZ- Wif1 allografts  
Using image software FIJI the proportion of blue stained collagen was calculated for each image. Each value 
represents the mean and the 95% CI of 11 tumors for which 3 images each were analyzed. Statistical significance 
was tested using mixed linear model.  * p< 0.05. 
 
As Wif1 can bind to HSGPs in the extracellular space we speculated whether 
Sdc-2, a main component of HSPGs, is also affected by Wif1 
overexpression. For this purpose, a Western blot was performed (see Fig. 






Fig. 46:  Western blot of Sdc-2 in ASZ -pMSCV and ASZ- Wif1 allografts 
Protein samples from in vitro cultures and from allografts (#96-109) were analyzed. Sdc-2 antibody detects total 
Sdc-2 protein with a size of 20 kDa. Hsc70 served as loading control. Please note that Hsc70 loading control in this 
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IV.5.2.6 Effect of Wif1 on proliferation in vivo 
In order to evaluate the impact of Wif1 overexpression on proliferative 
capacity of ASZ-pMSCV and ASZ-Wif1 derived tumors, 
immunohistochemical stainings of the S-phase associated marker Ki67 was 
performed.  
ASZ-Wif1 derived allografts revealed a significantly reduced number of Ki67 
positive nuclei per 1000 cells compared to ASZ-pMSCV derived allografts. 
This indicates that ASZ-Wif1 allografts show a lower proliferative capacity 
(see Fig. 47). 
 
Fig. 47: Evaluation of Ki67 staining of ASZ -pMSCV and ASZ- Wif1 allografts   
Total number of nuclei and Ki67 positive nuclei per paraffin section of ASZ-pMSCV and ASZ-Wif1 allografts were 
counted using image processing software FIJI. 3 images per section derived from 9 different tumor samples were 
analyzed for ASZ-pMSCV and ASZ-Wif1 derived allografts. Statistical significance was analyzed using Wilcoxon 
test. * p< 0.05.  
 
Since Wnt signaling is known to induce cyclin D1 expression (Shtutman et al. 
1999; Zhang et al. 2012), which is a key regulator of cell cycle progression, 
we also analyzed cyclin D1 protein expression levels by means of Western 
blot. However, no obvious differences in the expression levels between 
ASZ-pMSCV and ASZ-Wif1 derived tumors were observed (see Fig. 48). 
 









Fig. 48: Western blot of cyclin D1 in ASZ -pMSCV and ASZ- Wif1 allografts. 
Protein samples from in vitro cultures and from allografts (#96-109) were analyzed. Cyclin D1 antibody detects total 
cyclin D1 protein with a size of 36 kDa. Hsc70 served as loading control. 
 
Tumor-associated macrophages (TAMs) and cancer-associated fibroblasts 
(CAFs) are known to affect cancer cell proliferation (Bingle et al. 2002; 
Augsten 2014). For example, the reduced proliferation of ASZ-Wif1 derived 
tumors could have been a result of decreased infiltration with TAMs or CAFs. 
To investigate whether the latter cellular components show a different 
distribution in ASZ-pMSCV and ASZ-Wif1 derived tumors, antibody staining 
of F4/80 and alpha smooth muscle actin (αSma) as markers for TAMs and 
CAFs, respectively, was performed. 
 
Fig. 49: antibody staining of F4/80 in ASZ -pMSCV and ASZ- Wif1 allografts   
Antibody stainings of F4/80 (red) on paraffin sections derived from ASZ-pMSCV and ASZ-Wif1 allografts. Two 
examples each are shown. Staining reaction was performed using AEC. 
 
ASZ-pMSCV ASZ-Wif1 
Hsc70 (70 kDa) 
cyclin D1 (36 kDa) 
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Neither the quantity of F4/80 positive cells nor the staining pattern was 
obviously different between ASZ-pMSCV and ASZ-Wif1 derived allografts 
(see Fig. 49). Similar results were obtained with the αSma antibody that also 
did not show any differences concerning quantity of stained cells or staining 
pattern (see Fig. 50).  
 
Fig. 50: Antibody staining of αSma in ASZ -pMSCV and ASZ- Wif1 allografts  
Antibody stainings of αSma on paraffin sections derived from ASZ-pMSCV and ASZ-Wif1 allografts. Two examples 
each are shown. Staining reaction was performed using AEC. 
 
Together these results suggest that the infiltration of the tumors with TAM 
and CAF is not responsible for the different growth behaviour of ASZ-pMSCV 
and ASZ-Wif1 derived tumors.  
 
 
IV.5.3 Summary of the effects of Wif1 overexpressio n  
Overexpression of Wif1 in the BCC cell line ASZ001 resulted in reduced 
tumor growth when the cells were transplanted into nude mice. This did not 
involve Hh, Wnt or PI3K/Akt signaling, apoptosis, stromal composition or 
differentiation. Furthermore, it does not require an interaction with tumor-
associated fibroblasts or macrophages. Instead, the deposition of collagen 
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was increased and the proliferative capacity of the transplanted cells was 
reduced. This correlated with increased PKC and Erk1 phosphorylation which 
might indicate a putative role in EGF signaling.  
 
 
IV.6  Targeted disruption of Wif1 in murine BCC 
For further analysis of the function of Wif1 in vivo we employed the 
Ptchflox/floxCreERT2T/- BCC mouse model in which mice develop BCC upon 
tamoxifen induction. BCC of these mice express Wif1. The expression is 
already detectable 45d after tamoxifen induced BCC development (see Fig. 
52).  The expression persists at least 90 days after tamoxifen injection (see 
Fig. 52). As in humans (see Fig. 8) the expression is detected tumor 
intrinsically as well as in the tumor stroma with a highly heterogeneous 
distribution in the latter (see Fig. 51). 
 
 
Fig. 51: Antibody staining of Wif1 in murine BCC  
Anti-Wif1 antibody staining of paraffin sections derived from 45d (left) and 90d (right) BCC of Ptchflox/floxCreERT2T/- 
mice. Staining reaction was performed using AEC. 
 
In order to investigate whether BCC growth is dependent on Wif1, Wif1 
function was disrupted in BCC by breeding Ptchflox/floxCreERT2T/- mice with 
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Wif1-/- mice. In the Wif1-/- mouse model a LacZ-ORF is inserted into exon 1 of 
the Wif1 gene which results in several in frame stop codons and thus in loss 
of function of Wif1.  In the resulting offspring i.e. Ptchflox/floxCreERT2T/-Wif1-/- 
and Ptchflox/floxCreERT2T/- BCC were induced by tamoxifen injection at an age 
of 8 weeks. Both Ptchflox/floxCreERT2T/-Wif1-/- and Ptchflox/floxCreERT2T/- mice 
were randomized in 2 cohorts. In the first cohort BCC were analyzed 45 days 
after tamoxifen injection (45d) (Nitzki et al. 2010). The second cohort was 
analyzed 90 days after BCC induction. Wif1 wild-type littermates i.e. 
Ptchflox/floxCreERT2T/- and littermates lacking Cre-recombinase i.e. 
Ptchflox/floxWif1-/- served as controls. None of the littermates lacking Cre-
recombinase that were treated with tamoxifen developed BCC. In contrast, all 
Ptchflox/floxCreERT2T/- and Ptchflox/floxCreERT2T/-Wif1-/- animals developed 
tumors. Macroscopically no difference between both BCC backgrounds was 
detectable. As expected Wif1 protein was not detected in skin samples from 









Fig. 52: Western blot of Wif1 in murine BCC   
Skin samples from 45d and 90d cohorts of Ptchflox/floxCreERT2T/- and Ptchflox/floxCreERT2T/-Wif1-/- animals were 
analyzed regarding Wif1 protein expression.  
 
To assess the tumor load of Ptchflox/floxCreERT2T/- and 
Ptchflox/floxCreERT2T/-Wif1-/- animals the tumor size was measured on H&E 
stained paraffin sections (3 images from sections of 5 different animals each) 
using cellSens software. As demonstrated in Fig. 53 BCC of mice lacking 
Wif1 expression had the same size compared with Wif1 wild-type littermate 
45d after induction. However, in 90 day cohorts the size of BCC in mice 
lacking Wif1 expression was unambiguously larger compared with Wif1 











Hsc70 (70 kDa) 
Wif1(42 kDa) 




Fig. 53: Planimetric measurement of tumor size in Ptchflox/floxCreERT2T/- and Ptchflox/floxCreERT2T/-Wif1-/- skin 
samples 45d after induction  
3 images of each 5 Skin samples from Ptchflox/floxCreERT2T/- and Ptchflox/floxCreERT2T/-Wif1-/- animals were analyzed 
using software cellSens.  
 
 
Fig. 54: Planimetric measurement of tumor size in Ptchflox/floxCreERT2T/- and Ptchflox/floxCreERT2T/-Wif1-/- skin 
samples 90d after induction 
3 images of each 5 Skin samples from Ptchflox/floxCreERT2T/- and Ptchflox/floxCreERT2T/-Wif1-/- animals were analyzed 
using software cellSens.  
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Next, in order to investigate the proliferative capacity of the tumors, an 
anti-Ki67 antibody staining was performed on paraffin embedded sections. 
As shown in Fig. 55 the percentage of Ki67 positive cells was significantly 
higher on a Wif1 deficient background in both, the 45d and 90d, cohorts.  
Together, these data indicate that in accordance with the allograft 
experiments (see Fig. 26) Wif1 is a factor that is neccessary to restrict BCC 
growth.   
  
Fig. 55: Evaluation of anti-Ki67 antibody staining  in Ptchflox/floxCreERT2T/- and Ptchflox/floxCreERT2T/-Wif1-/- skin 
samples 45d and 90d after induction 
Ki67 positive cells were counted using AlphaView software. 3 images of 3 skin samples each were analyzed. 
Exclusively BCC cells were counted. All data are represented as a mean + SEM. Statistical significance was 









V.1  WIF1 in human tumors of the skin  
As shown by antibody staining, WIF1 is highly expressed in human and also 
murine BCC. Indeed, all analyzed human BCC samples exhibited tumor-
intrinsic WIF1 expression. This is in line with data from the human protein 
atlas webpage where 5 out of 6 samples from BCC patients were described 
to express at least weak WIF1 protein levels in antibody stainings.  
Using immortalized rat kidney cells it was found that GLI1 transduction 
induced the expression of Wif1 (Louro et al. 2002). Because at that time 
WIF1 was already known as a potential tumor suppressor gene, the authors 
already speculated that WIF1 expression may be responsible for the 
infrequent occurrence of metastases in BCC patients (Louro et al. 2002). 
Even though this speculation was not formally proven, the authors proposed 
that a Wif1 knockout could demonstrate its tumor suppressive function in skin 
cancer. In line with this assumption, WIF1 was found to be downregulated in 
melanomas compared with nevi (Haqq et al. 2005). Taken together, this 
drove us to hypothesize that Wif1 might keep BCC semi-malignant and 
prevents it from malignant transformation. We also speculated that WIF1 is 
absent or present at significantly lower levels in invasive BCC, SCC and 
malignant melanomas compared to indolent-growth subtypes of BCC. 
However, as shown by our data this was not the case.  
In our experiments we used qRT-PCR to quantify WIF1 expression in 
indolent-growth and invasive variants of BCC, SCC and malignant 
melanomas. Whereas antibody staining does not allow comparative 
quantification of gene expression in different tumor samples and entities, 
qRT-PCR does. Thus, laser microdissection of paraffin-embedded tumor 
tissue was performed and WIF1 mRNA levels were analyzed. WIF1 
expression in invasive BCC, SCC and melanomas was at comparable levels 
and expression in SCC and melanomas was significantly higher compared to 
the indolent-growth variants of BCC, i.e. superficial and nodular BCC. 
Although this contradicted our working hypothesis that WIF1 is a tumor 
suppressor in BCC and as such should be expressed at higher levels in 
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indolent-growth subtypes of BCC when compared to more malignant skin 
tumors, our consecutive data showed that Wif1 inhibited BCC growth in 
mouse models. This leaves several possibilities for interpretation: First, Wif1 
exerts its tumor suppressive functions only in the mouse. However, this is 
unlikely since there is only one report suggesting an oncogenic function of 
WIF1, whereas all other studies unambiguously showed that WIF1 acts as a 
tumor suppressor in diverse human tumor entities. Furthermore, in 
melanoma WIF1 gene transfer was shown to inhibit tumor growth in a 
xenograft model by suppressing proliferation (Lin et al. 2007). This supports 
the hypothesis of WIF1 being a tumor suppressor also in malignant skin 
tumors. Second, WIF1 could also have distinct functions in BCC, SCC and 
melanoma. For example, WIF1 promotes melanogenesis in melanocytes 
(Park et al. 2014) suggesting a distinct function in melanomas compared with 
BCC and SCC. Third, I only have determined WIF1 expression on mRNA 
level ignoring possible post-transcriptional, translational and post-
translational regulatory mechanisms.  
Another aspect about WIF1 expression in BCC is the following: Although 
invasive BCC express higher WIF1 levels than indolent–growth subtypes the 
differences of WIF1 expression were statistically not significant. This might 
be different if a larger sample set would have been analyzed. In case this 
would be true, there would be an explanation to it: GLI1 was shown to induce 
Wif1 expression in rat kidney cells (Louro et al. 2002). Furthermore, Gli1 is 
the effector driving tumor formation in BCC (Nilsson et al. 2000). Thus 
elevated GLI1 activity in invasive BCC could be the cause for elevated WIF1 
expression levels. However, so far this is pure speculation because GLI1 
mRNA levels in invasive versus indolent-growth variants of BCC have not 
been quantified. Prospectively, this experiment will be conducted in our lab 
using the samples from the microdissections.  
Noteworthy, beside tumor-intrinsic expression WIF1 was obviously also 
highly expressed in cells of inflammatory infiltrates and in fibroblasts of the 
tumor stroma (see Fig. 8). WIF1 expression in fibroblasts of the skin has 
been previously reported to be involved in melasma development (Kim et al. 
2013). In contrast, the role of WIF1 in inflammation of the skin is currently 
absolutely unknown. However, it was shown that abrogation of Wnt secretion 
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in keratinocytes resulted in infiltration of immune cells and inflammation of 
the skin (Augustin et al. 2013). This might also suggest an implication of 
WIF1 in the promotion of inflammation by inhibiting Wnt signaling.  
Thus, WIF1 seems to exert a variety of functions in the skin and it cannot be 
ruled out that tumor-extrinsic WIF1 also affects BCC development. However, 
in this thesis I will focus on the putative tumor suppressive function of tumor-
intrinsic WIF1 as this appears to be a general phenomenon that applies for a 
variety of different cancer entities. 
 
 
V.2   Wif1 overexpression in the BCC cell line 
ASZ001 
ASZ001 is the only available BCC cell line derived from Ptch+/- mice. Even 
though derived from a tumor that exhibited Wif1 expression, this cell line 
expresses Wif1 at low to undetectable levels (data not shown). This is in line 
with lost WIF1 expression in human cultured proliferating keratinocytes 
(Schluter et al. 2013). Thus, a Wif1 overexpression plasmid was generated. 
Using the stably transduced cell line ASZ-Wif1 the effect of Wif1 on BCC 
growth was examined.  
 
 
V.2.1 Validation of Wif1 overexpression, secretion and 
functionality 
Effective Wif1 overexpression in ASZ-Wif1 cells was shown on RNA as well 
as protein level (see Fig. 12 and Fig. 13). Since Wif1 is a secreted protein 
exhibiting its function in the extracellular space by sequestration of Wnt 
ligands, its secretion was analyzed by concentrating the medium of ASZ-Wif1 
and subsequent Western blot analysis. In fact, Wif1 is secreted by ASZ-Wif1 
into the medium (see Fig. 14).  Unfortunately, I was not able to analyze the 
functionality of the secreted Wif1 by TOP/FOP reporter assay when the 
parental cell line ASZ001 was used. This was due to the fact that neither 
Wnt3a nor an active form of β-catenin induced TOP activity in this cell line. 
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TOP activity is dependent on functional Lef1 which binds to Tcf/Lef binding 
sites of the TOP vector when activated by β-catenin. Thus, it is possible that 
ASZ001 simply does not express a functional form of Lef1. Alternatively, the 
transduction efficiency was insufficient to facilitate luciferase expression. 
Therefore, HEK-293 cells were employed as an alternative. In this 
experimental setup concentrated supernatant from ASZ-Wif1 significantly 
inhibited the action of Wnt3a conditioned medium as measured by the 
TOP/FOP reporter assay. This demonstrated that functionally active Wif1 
was successfully overexpressed and secreted by ASZ-Wif1 cells. Therefore, 
ASZ-Wif1 cells served as basis for subsequent investigations on the role of 
Wif1 in BCC. 
 
 
V.2.2 Effects of Wif1 overexpression on the BCC cel l 
line ASZ001 
The effect of Wif1 overexpression on BCC cell growth was analyzed in vitro 
and in vivo. For in vivo analyses the cell lines ASZ-Wif1 and ASZ-pMSCV 
were subcutaneously transplanted in the flanks of nude mice.  
Similarly to xenografts of melanoma, kidney cancer and cervical cancer cells 
(Lin et al. 2007; Kawakami et al. 2009; Ramachandran et al. 2012) the 
overexpression of Wif1 resulted in reduced BCC growth (see Fig. 26) which 
was also reflected by reduced tumor weight (see Fig. 27). Reduced tumor 
growth can be a result of alterations in diverse cellular processes. Therefore, 
I examined the effect of Wif1 on signaling pathway activity, cell viability, 
apoptosis, differentiation, EMT, migration, cell cycle regulation, proliferation, 
and on the tumor microenvironment. 
 
 
V.2.2.1 Effect of Wif1 on Wnt, Hh and EGFR signalin g 
pathways  
It has been shown that shifted, the Drosophila orthologue of Wif1, increased 
stabilization and diffusion of Hh (Glise et al. 2005) and promoted Hh signaling 
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mediated by Hh co-receptors interference hedgehog (Ihog) and brother of 
Ihog Boi (Avanesov and Blair 2013). Furthermore, overexpression of Wif1 in 
hematopoietic stem cells induced Shh expression resulting in Hh pathway 
activation (Schaniel et al. 2011). As these results suggested that Wif1 may 
also induce Hh signaling in BCC, Hh signaling activity was determined by 
Gli1 qRT-PCR in ASZ-Wif1 and ASZ-pMSCV cells. However, overexpression 
of Wif1 did not alter Gli1 gene expression neither in vitro nor in vivo (see Fig. 
17 and 31). Although ASZ001 were derived from BCC that had activated Hh 
signaling, they express relatively low Gli1 mRNA levels (So et al. 2006). 
Thus, we would have expected an upregulation of Gli1 expression if Wif1 
would have been able to activate Hh signaling. Taken together, it can be 
hypothesized that ASZ001 either i) lacks required coreceptors, ii) is not able 
to upregulate Shh or iii) is insensitive towards Shh due to its Ptch mutation. 
On the contrary, it has been shown that Wif1 is downstream of Gli1 as GLI1 
transduction induced Wif1 expression in rat kidney cells (Louro et al. 2002). 
Moreover, the Wif1 promoter region contains a GLI-kruppel binding site as a 
regulatory element (Reguart et al. 2004), suggesting that Wif1 is downstream 
and not upstream of activated Hh signaling in BCC. If this is also true for Wif1 
expression in ASZ001 it consequently did not alter Hh signaling in ASZ-Wif1 
cells and allografts.  
As a Wnt inhibitor Wif1 can bind to several Wnts and prevent them from 
binding to their receptors. Activated canonical Wnt signaling leads to a 
translocation of β-catenin into the nucleus and ultimately to the induction of 
target gene expression including Axin2 and c-Myc. In order to analyze 
whether the overexpression of Wif1 is sufficient to inhibit canonical target 
gene expression, the expression of Axin2 and c-Myc was analyzed by 
qRT-PCR. In addition, the subcellular localization of β-catenin was estimated 
by antibody staining. No changes in the target gene expression and no 
nuclear β-catenin were detectable (see Fig. 17, 31 and 32). Although nuclear 
β-catenin is currently debated as a reliable read-out for active canonical Wnt 
signaling, absence of nuclear β-catenin in combination with the unaffected 
target gene expression strongly suggests that canonical Wnt signaling is 
inactive in the ASZ001-derived cell lines and respective allografts. Thus, it is 
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possible that Wif1 overexpression was not able to further decrease the 
already very low levels of Axin2 and c-Myc.  
Next, the activation status of Wnt/Ca2+ and Wnt/PCP pathways were 
determined as Wif1 is able to bind and inhibit several Wnts that are 
implicated in activation of non-canonical Wnt signaling (e.g. Wnt4, 5a, 7a and 
11) (Surmann-Schmitt et al. 2009; Vassallo et al. 2015). However, JNK as 
mediator of active Wnt/PCP pathway was unphosphorylated. This rather 
suggests inactive Wnt/PCP signaling. Furthermore, the cytoplasmic Ca2+ 
levels of ASZ-pMSCV and ASZ-Wif1 as an indicator for activated Wnt/Ca2+ 
signaling were examined. Neither the the basal Ca2+ concentrations nor the 
maximum Ca2+ flux ratio was altered in ASZ-Wif1 (see Fig. 18). This 
indicates that Wnt/Ca2+ signaling is either not affected by Wif1 or that the 
sensitivity of this assay does not allow for discrimination between small 
differences in Ca2+ concentrations. Moreover, CaMKII was unphosphorylated 
in allografts and in in vitro samples supporting that Wnt/Ca2+ signaling is not 
affected.  
However, I found PKC phosphorylation to be upregulated in vitro and to be 
maintained in ASZ-Wif1 allografts. The antibody detects PKC isoforms α, βI, 
βII, δ, ε, η and θ (78-85 kDa) when phosphorylated at serine 660. Due to the 
minor differences in the size of the isoforms they cannot be discriminated by 
Western blot analysis. However, PKC α, β and δ isoforms are expressed in 
keratinocytes and BCC (Neill et al. 2003; Breitkreutz et al. 2007). 
Interestingly, loss of PKC α is associated with enhanced tumor growth in 
BCC (Neill et al. 2003). Previous results of our group showed that an 
antibody detecting α and βII isoforms recapitulated pan-PKC expression in 
BCC samples (Carstens 2010). Thus, it is highly probable that the detected 
PKC was constituted of α and βII isoforms.  
The aspect about PKC phosphorylation is of particular interest as PKC is not 
only involved in Wnt/Ca2+ signaling but also mediates EGFR (Fan et al. 
2009). As Wif1 contains 5 EGF-like domains, all high-affinity ErbB ligands 
contain an EGF-like domain (Yarden and Sliwkowski 2001) and since Ca2+ 
was not affected in ASZ-Wif1 cell lines, it is tempting to speculate that Wif1 
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might also have affected EGFR signaling. Indeed, one investigation identified 
Wif1 as a binding partner for ErbB2, 3 and 4 that are isoforms of the EGFR 
(Curak 2010). Since BCC usually express EGFR (Eberl et al. 2012) and 
because EGFR activity can result in activation of Akt and Ras signaling the 
phosphorylation status of Akt, S6 and Erk1/2 was analyzed. Akt and S6 
display an inconsistent phosphorylation pattern, which however did not 
significantly vary between ASZ-Wif1 and ASZ-pMSCV allografts. Erk1 and 2 
were both phosphorylated und thus activated when the cell lines were 
cultured in vitro with slightly increased phosphorylation of Erk1 in ASZ-Wif1. 
Interestingly, when the cell lines were transplanted in nude mice, the 
phosphorylation status of Erk2 remained at equal levels in both cell lines. In 
contrast, Erk1 phosphorylation was only maintained in the ASZ-Wif1 
allografts whereas it vanished in ASZ-pMSCV allografts.  
Firstly, these data may indicate that Erk1 phosphorylation in the in vitro 
situation is fostered by specific growth factors provided by FCS that is a 
supplement of the culture medium. The fact that Erk1 phosphorylation was 
maintained exclusively in ASZ-Wif1 allografts could be a result of the 
concomitantly observed maintenance of PKC phosphorylation. Moreover, it 
could be part of activated Wnt/Ca2+ signaling or active EGFR signaling (see 
above) (Kolch 2005; Mendoza et al. 2011). Whether the maintenance of PKC 
and Erk1 phosphorylation is indeed part of one or both signaling pathways 
and how and whether Wif1 participates in this process remains to be 
elucidated in the future.  
Secondly, the maintenance of Erk1 phosphorylation in ASZ-Wif1 cells may 
be related to inhibition of tumor growth. Although, at the first glance this 
seems to come into conflict with the traditionally regarded role of pERK1/2 as 
tumor promoters, overexpression of ERK1 in NIH/3T3 cells inhibits Ras-
mediated proliferation and tumorigenicity while ERK2 does not (Vantaggiato 
et al. 2006). Furthermore, it has been reported that the cell cycle is promoted 
when Erk1/2 is persistently and moderately activated, while transient Erk1/2 
activation fails to do so (Yamamoto et al. 2006). In addition, sustained 
Raf/Mek/Erk pathway over-activation can trigger cell cycle arrest (Samuels et 
al. 1993; Guegan et al. 2014), which can be mediated by elevated expression 
levels of the cell cycle inhibitor p21cip1 that blocks cyclin E/CDK2 complexes 
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inhibiting S-phase entry (LaBaer et al. 1997; Sewing et al. 1997). Finally, 
temporally elevated Erk1/2 activation at the G2/M transition can block entry 
into mitosis (Rahmouni et al. 2006). Thus, the consequence of Erk1/2 
signaling is considered to depend on the duration, intensity and time point of 
activation. Accordingly, it is possible that persistent high Erk1 activation in 
combination with sustained Erk2 activity in ASZ-Wif1 cells may have resulted 
in cell cycle arrest and thus could ultimately explain the reduced tumor 
growth of ASZ-Wif1 allografts. This highly interesting topic will be 
investigated in the future. 
In this context it is also interesting to know,  that Erk1 and 2 share about 84% 
amino acid sequence identity, that they are coexpressed in most tissues, 
have similar subcellular localization, substrate specificity and stimuli leading 
to their activation (Samuels et al. 2008; Guihard et al. 2010; Woodson and 
Kedes 2012). Thus, most investigations did not discriminate between both 
isoforms. However, and as already mentioned above, increasing evidence 
supports distinct functions and different outcomes of Erk1 and Erk2 
phosphorylation (Pages and Pouyssegur 2004). First hints that they execute 
different functions came from observations that the levels of Erk1 and Erk2 
vary depending on the tissue context (Pages and Pouyssegur 2004). 
Subsequently, it was shown that loss of ERK1 significantly facilitated 
proliferation in contrast to knockdown of ERK2 which resulted in reduced 
proliferation. Vice versa and as already mentioned above, overexpression of 
ERK1 in NIH/3T3 cells inhibited Ras-mediated proliferation and 
tumorigenicity while ERK2 does not. Notably, ERK1 function was kinase-
independent in this case, as expression of a catalytically inactive form of 
ERK1 was equally effective (Vantaggiato et al. 2006). The authors proposed 
a model in which ERK1 and ERK2 compete in binding to the upstream kinase 
MEK. By means of this molecular process ERK1 negatively interferes with 
the growth promoting ERK2 signaling. However, coming back to ASZ-Wif1 
cells the total amounts of Erk1 and 2 were not significantly altered but Erk1 
phosphorylation was maintained in vivo. Thus, a distinct mechanism may be 
involved for the tumor-suppressive role of Erk1 in ASZ-Wif1 cells. Indeed, it 
was hypothesized that Erk1 is a partial agonist of Erk signaling. Thus, Erk1 
may bind to the same signaling effectors but is not able to elicit the maximum 
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possible response that is produced by the full agonist Erk2. With increasing 
ratios of Erk1 to Erk2 activity this would result in the inhibition of Erk signaling 
(Brambilla and Ratto 2009). Thus, increased phosphorylation of Erk1 could 
possibly inhibit growth promoting effect of Erk2 by competing with its 
signaling effectors, thereby suppressing ASZ-Wif1 tumor growth in vivo. 
However, this is pure speculation and remains to be established in the future. 
 
 
V.2.2.2 Effect of Wif1 on proliferation 
In line with inhibition of proliferation in keratinocytes (Schluter et al. 2013) 
and with the above-mentioned speculations about the relation of Erk1 and 
Erk2 activation levels, proliferation and growth of ASZ-Wif1 allografts was 
suppressed. This was shown by decreased tumor size and weight, which 
went along with a significantly reduced number of Ki67 positive tumor cells 
(see Fig. 47). This showed that Wif1 can suppress tumor growth of BCC cells 
in vivo.  
Wif1 has been shown to induce a G1 cell cycle arrest in invasive bladder 
cancer cell lines (Tang et al. 2009) and to suppress proliferation in 
keratinocytes of the interfollicular epidermis (Schluter et al. 2013). Indeed, an 
in vitro cell cycle analysis showed that ASZ-Wif1 cells had the tendency to 
accumulate in G1 phase, however this was statistically not significant (see 
Fig. 21). In addition, the in vitro analysis revealed no significant differences 
between ASZ-Wif1 and ASZ-pMSCV cells by BrdU assay (see Fig. 22). As 
Wif1 overexpression did not suppress proliferation in vitro but in vivo we 
initially hypothesized that the Wif1-mediated inhibition of proliferation in vivo 
might require a crosstalk with the tumor microenvironment. Within the 
microenvironment TAMs and CAFs play essential roles in the regulation of 
tumor cell proliferation (Bingle et al. 2002; Augsten 2014). Therefore, 
ASZ-Wif1 and ASZ-pMSCV cells were cocultured with several fibroblast cell 
lines and BMDMs and the proliferative capacity of the BCC cell lines were 
analyzed. However, no significant difference of the proliferation between both 
cell lines was observed (see Fig. 23). Thus, the in vivo inhibition of 
proliferation caused by Wif1 cannot only be explained by an interaction with 
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fibroblasts (simulating CAFs) or BMDMs (simulating TAMs) and must rely on 
additional or different cellular and/or molecular components. Alternatively, 
and as outlined in the previous section, the Wif1-mediated inhibitory effect on 
BCC cell proliferation might depend on maintenance of Erk1 phosphorylation 
in ASZ-Wif1 cells, which may have required cultivation in the absence of 
FCS. In conclusion, Wif1 inhibits the proliferation of ASZ001 in vivo but not in 
vitro, at least not in the presence of FCS.  
 
 
V.2.2.3 Effect of Wif1 on apoptosis  
Since the proliferative capacity of tumor cells is frequently negatively 
correlated with their metabolic activity and apoptotic processes, WST-1 
assay and Annexin V staining were performed. Indeed, WIF1 induces 
caspase mediated apoptosis in cervical cancer and hepatocellular carcinoma 
cells (Hu et al. 2009; Ramachandran et al. 2012). Moreover, active Erk1/2 
signaling can be associated with both, suppression and induction of 
apoptosis (Cagnol and Chambard 2010). However, overexpression of Wif1 
neither reduced in vitro cell viability as shown by WST-1 assay nor induced 
cell death as revealed by analysis of Caspase 3 cleavage and Annexin V 
assay. In accordance, ASZ-Wif1 allografts did not show hints for cell death as 
determined by TUNEL and p53 antibody staining. Thus, the reduced growth 
of ASZ-Wif1 allografts did not seem to involve the induction of apoptosis. 
 
 
V.2.2.4 Effect of Wif1 on differentiation 
As Wif1 expression has been shown to induce differentiation of several 
cancer entities and also regulates differentiation processes during 
development (Ramachandran et al. 2014; Baker et al. 2015), I determined 
whether reduced BCC proliferation was accompanied by an induction of 
keratinocyte differentiation marker expression. For this reason, the 
expressions of early markers (loricrin and involucrin) as well as markers for 
late differentiation (keratin 1 and 10) were analyzed in the ASZ-derived 
V          Discussion 
113 
 
allografts. However, no significant differences were detectable. The lack of 
difference in gene expression together with similar proportions of 
keratinization in allograft sections (see Fig. 25, 37 and 38) indicates that the 
anti-proliferative effect mediated by Wif1 is unrelated to induction of 
differentiation processes.  
 
 
V.2.2.5 Effect of Wif1 on EMT 
EMT is a prerequisite for the induction of migration that could lead to 
extravasation and ultimately to metastasis. Thus, migration can serve as a 
read out for in vitro induction of EMT in epithelial cells (Kalluri and Weinberg 
2009). Since Wif1 can induce EMT reversal and can inhibit migration and 
invasion in prostate cancer cells (Yee et al. 2010), the impact of Wif1 on 
expression of EMT marker genes and migration was determined.  
In vitro, Wif1 did no change the migratory capacity of ASZ001 (see Fig. 24). 
In accordance with this, the expression of EMT markers Cdh1, Cdh2 and Fn1 
did not differ between ASZ-Wif1 and ASZ-pMSCV allografts. This is in line 
with the microscopically unaffected cell morphology in vitro. Admittedly, we 
did not expect a significant difference in EMT marker expression or migration 
as ASZ001 already show a strict epithelial phenotype. In addition, these cells 
are derived from a well differentiated semi-malignant tumor entity, which is 
maintained when the cells were transplanted in mice and formed tumors (see 
Fig. 28). Taken together, we conclude that Wif1 probably does not affect 
EMT in BCC. Furthermore, Wif1 seems to be unable to induce a more 
epithelial phenotype of an already well differentiated epithelial tumor. 
 
 
V.2.2.6 Effect of Wif1 on the tumor microenvironmen t 
As discussed in section IV.5.2.6 antibody staining of the S-phase marker 
Ki67 showed reduced proliferation of ASZ-Wif1 derived tumors. Since 
invasion of TAMs and CAFs can affect tumor growth, antibody stainings 
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using an anti-F4/80 antibody and an anti-αSma antibody, respectively, were 
conducted. 
TAMs and CAFs can either promote or inhibit tumor growth and the 
respective outcome is apparently context-specific (Bingle et al. 2002; 
Augsten 2014). TAMs and CAFs secrete a variety of growth factor, including 
EGF, hepatocyte growth factor (HGF), basic fibroblastic growth factor 
(bFGF), vascular endothelial growth factor (VEGF) and platelet derived 
growth factor (PDGF) (Koontongkaew 2013) that can modulate tumor growth. 
Thus, the recruitment or absence of TAMs and/or CAFs could have been a 
cause of the growth inhibitory effect of Wif1.  
However, no obvious differences in the number of F4/80 and αSma positive 
cells were detected in ASZ-Wif1 and ASZ-pMSCV derived tumors when 
stained with the respective antibodies (see Fig. 49 and 50). Admittedly, this 
does not categorically exclude differences in e.g. activity or secretion of 
growth factors of TAMs or CAFs. However, the similar infiltration pattern of 
the tumor samples together with the fact that the corresponding coculture 
experiments also did not result in proliferation changes of the BCC cells (see 
section IV.4.3 and Fig. 23) kept us from further extensions of the 
experiments. 
Furthermore, extracellular matrix (ECM) proteins including collagens can 
significantly influence tumor growth and invasiveness. This is due to the fact 
that tumor progression directly depends on the ECM composition, structure 
and organization (Yu et al. 2011). Traditionally, ECM deposition is considered 
as an antagonistic response of the host stroma to the development of the 
tumor.  
Undoubtedly, tumor cells change their microenvironment to ensure their 
survival (Bissell and Radisky 2001). Furthermore, previous data showed that 
inhibition of integrins that mediate cell-ECM interactions results in restoration 
of a “close-to-benign” phenotype of tumor cells (Weaver et al. 1997). 
Moreover, it is well known that tumor-derived ECM is biochemically distinct in 
its composition compared to normal ECM. This is responsible for a stiffening 
of the tumor stroma compared to normal stroma (Kass et al. 2007; Levental 
et al. 2009). Thus, ECM deposition has been linked to tumor growth.  
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However, in contrast it also has been reported that overexpression of type I 
collagen, which is a main component of the ECM, can reduce tumor growth 
in vivo (Honma et al. 2007).  
Due to the importance of ECM in tumor growth processes, the collagen 
deposition was analyzed in ASZ-derived allograft sections by means of 
Ladewig staining. Collagen deposition was significantly increased in deeper 
necrotic areas of ASZ-Wif1 allografts when compared to ASZ-pMSCV 
allografts. Outer regions of the allografts with mainly vital tumor tissue 
showed a tendency of elevated collagen levels that, however, was not 
significant. Nevertheless, it would be certainly of interest to study the effects 
of Wif1 on production of collagen and thus on ECM in more detail. In 
addition, it would be also interesting to analyze whether Wif1 changes the 
composition of the ECM or modulates the expression of e.g. 
metalloproteases that are well known ECM degrading enzymes.  
Admittedly, it remains to be said that the increased amount of collagen found 
in the necrotic tumor regions may have originated from the Matrigel that 
served as substrate for the cells transplanted cells into nude mice.  
Nevertheless, the collagen accumulation in ASZ-Wif1 allografts is an 
interesting feature that certainly deserves further investigations. 
 
 
V.3 Wif1 depletion in murine BCC 
The tumor suppressive role of Wif1 in BCC was verified in a genetic 
approach. Wif1 disruption led to tumor promotion, which supported the anti-
tumorigenic role of Wif1 in BCC. In this genetic approach the 
Ptchflox/floxCreERT2T/- BCC mouse model was bred onto a Wif1 deficient 
background. The resulting Ptchflox/floxCreERT2T/-Wif1-/- offspring lacked Wif1 
expression in BCC as estimated by Western blot. Ptchflox/floxCreERT2T/- and 
Ptchflox/floxWif1-/- littermates served as controls. For each genotype 2 cohorts 
were sacrificed 45d and 90d after tamoxifen injection. Macroscopically, first 
tumors were visible about 4 weeks after tamoxifen injection in 
Ptchflox/floxCreERT2T/-Wif1-/- and Ptchflox/floxCreERT2T/- mice without significant 
differences between the genotypes. As expected Cre lacking Ptchflox/floxWif1-/- 
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mice remained tumor free. In the cohorts that were sacrificed 45d after 
tamoxifen injection both Ptchflox/floxCreERT2T/-Wif1-/- and Ptchflox/floxCreERT2T/- 
mice developed histologically confirmed BCC. At that time the tumor load of 
the animals was undistinguishable. Taken together with lacking differences in 
tumor onset, this suggests that Wif1 does not affect tumor initiation. 
However, when the animals were sacrificed 90d after tumor induction the 
tumor load of Ptchflox/floxCreERT2T/-Wif1-/- was significantly increased when 
compared to Ptchflox/floxCreERT2T/- mice. In addition, we confirmed the 
enhanced proliferative capacity of the tumors as the number of Ki67 positive 
cells was significantly higher in tumors lacking Wif1. Together, this 





Planimetric measurement and Ki67 staining show that BCC growth is 
enhanced in Ptch knockout mice on a Wif1-deficient background. Vice versa, 
tumor-intrinsic Wif1 overexpression in the BCC cell line ASZ001 inhibits 
tumor growth in mice. This does not involve apoptosis, Akt, Wnt or Hh 
signaling or activation of apoptosis. It also does not involve changes in tumor 
differentiation or alterations in stromal composition of transplanted cells in 
host mice. Furthermore it does not seem to require an interaction with tumor 
associated fibroblasts or macrophages. Because tumor-intrinsic Wif1 
expression only inhibits cellular proliferation in vivo but not in vitro the data 
suggest that Wif1 probably prevents tumor-promoting effects of soluble Wnt 
or other factors secreted by the tumor environment.  
The tumor suppressive effect of Wif1 was exclusively observed in vivo. Thus, 
Wif1 could elicit its effects via two potential mechanisms. First, secreted Wif1 
may result in the activation of Wnt/Ca2+ or affect EGFR signaling and 
ultimately lead to PKC and Erk1 phosphorylation of the secreting cells in an 
autocrine fashion. Second, secreted Wif1 may also affect cells of the tumor 
stroma in a paracrine fashion. Mediated by the inhibition of Wnt signaling or 
by affecting EGFR signaling in adjacent stromal cells, Wif1 might change the 
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secretome of these cells, which in turn could result in the outcome described 
above (see Fig. 56). In order to elucidate whether paracrine signaling 
mechanisms are participating in the observed molecular events one could 
perform expression analyses using antibody staining or Western blot 
detecting putatively involved signaling molecules comparing ASZ-Wif1 and 
ASZ-pMSCV allografts.  
 Fig. 56: Putative autocrine and paracrine signalin g mechanism in ASZ- Wif1 allografts 
 
To examine the causative mechanism underlying these observations one 
should firstly analyse the proliferative capacity of ASZ-Wif1 in the absence of 
FCS, because the surplus of growth factors in FCS may have impeded the 
Wif1-dependent inhibition of proliferation in vitro. Furthermore, in the same 
experimental setting an incubation of ASZ-pMSCV with concentrated 
ASZ-Wif1 supernatant would confirm whether Wif1 inhibits proliferation. 
Most interestingly, the Wif1-mediated prevention of in vivo tumor growth was 
accompanied by maintenance of phosphorylation of PKC and Erk1 that was 
already seen in cell cultures, whereas phosphorylation of both proteins 
vanished in the faster growing control cells. This indicates that Wif1 may 
permit Wnt/Ca2+ signaling mediated by PKC phosphorylation resulting in Erk1 
activation. Alternatively, Wif1 might also affect EGFR signaling. 
Nevertheless, specific inhibition of Erk1 would demonstrate whether Erk1 
phosphorylation could result in the suppression of proliferation. Unfortunately, 
specific Erk1 inhibitors are not available. However, inhibition of Mek1/2 by 
U0126 resulting in inhibition of Erk1/2 was shown to inhibit proliferation of 
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ASZ001 (Xie et al. 2001). Therefore, one should also anticipate an Erk1 
knockdown/-out experiments in ASZ-Wif1 cells. This experiment would help 
to elucidate the function of Erk1 in proliferation in vitro and tumor growth 
suppression in an allograft experiment. 
To investigate whether EGFR signaling participates in Erk1 activation, protein 
samples from the respective in vitro cultures as well as allograft samples 
should be analyzed regarding EGFR signaling activity. First, the 
phosphorylation status of EGF receptors ErbB2, ErbB3, and ErbB4 that are 
able to bind Wif1 should be determined. Downstream of ErbB, receptor 
components of the signaling pathway that are known to be regulators of Erk1 
activity (e.g. Ras, Raf, Mek1) and effector proteins that are known to be 
regulated by Erk1 and control proliferation should be analyzed regarding their 
activity in subsequent experiments.  
In summary, our data indicate that Wif1 exerts a tumor suppressive function 
in BCC. Therefore, it might be worth testing purified and concentrated, 
topically applied Wif1 in a therapeutic treatment approach in the Ptch mouse 
model for BCC. 
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VII  Abbreviations 
#     number 
%     percent 
&    and 
 ‘     minute 
‘’    second 
°     degree 
µ     micro 
∞     unlimited 
+    positive 
+    wild-type 
-    minus 
-    knockout 
A     Ampere 
Ab     antibody 
ad libitum    lat. at liberty 
AEC    3-amino-9 ethylcarbazole 
AG     stock company (german: Aktiengesellschaft) 
Akt     v-akt murine thymoma viral oncogene homolog 
Ankrd     ankyrin repeat domain 
Apc     adenomatosis polyposis coli  
a.u.     arbitrary unit 
Axxx       absorbance at xxx nm 
b    y-intercept 
BAD     BCL2 antagonist of cell death 
BCC     basal cell carcinoma 
Bcl2    B cell leukemia/lymphoma 2 
Bcl9    B cell CLL/lymphoma 9  
BCNS    basal cell nevus syndrome 
bFGF     basic fibroblastic growth factor  
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Boc  biregional cell adhesion molecule-related/down-
regulated by oncogenes (Cdon) binding protein  
Boi     brother of Ihog  
bp     base pair 
BrdU     5-bromo-2’-deoxyuridine 
BSA     bovine serum albumin 
C     Celsius 
c     centi 
c     concentration 
Ca2+    calcium 
CaCl2     calcium chloride 
CAFs    cancer-associated fibroblasts 
CaMKII   calcium/calmodulin-dependent protein kinase II 
Cbp     CREB-binding protein 
CD    cluster of differentiation 
Cdh    cadherin  
CDK     cyclin-dependent kinase 
cDNA     complementary DNA 
Cdo1    cysteine dioxygenase 1, cytosolic  
Ci     cubitus interruptus 
CM     conditioned medium 
CMV     cytomegalovirus 
Cn    calcinurin 
Co.     company 
CO2    carbon dioxyde 
Cre    causes recombination 
Creb     cAMP responsive element binding protein 
Csnk1a1   casein kinase 1, alpha 1  
Ct     threshold cycle 
C-terminal   carboxyterminal 
Daam1  Dvl associated activator of morphogenesis 1 
dATP    2'-deoxyadenosine 5'-triphosphate 
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DAG    1,2 diacylglycerol 
DB    batabase 
dCTP    2'-deoxycytidine 5'-triphosphate 
ddH2O    double-distilled water 
del    deleted, deletion 
dGTP    2'-deoxyguanosine 5'-triphosphate 
Dhh     Dessert hedgehog 
Disp     Dispatched 
Dkk     dickkopf  
DMEM    Dulbecco’s modified eagle medium 
DMSO    dimethyl sulfoxide 
DNA     deoxyribonucleic acid 
DNase   deoxyribonuclease 
dNTP     deoxynucleotide 
dpc     days post coitum 
Drl     derailed 
DTT     dithiothreitol 
dTTP    2'-deoxythymidine 5'-triphosphate 
Dvl     dishevelled  
E. coli    Escherichia coli 
ECM    extracellular matrix 
e.g.     exempli gratia (lat. for example) 
EDTA    ethylenediaminetetraacetic acid 
EGF    epidermal growth factor 
EGFR    epidermal growth factor receptor 
EGTA    ethylene glycol tetraacetic acid 
eGFP     enhanced GFP 
EMT    epithelial-to-mesenchymal transition 
ER    endoplasmic reticulum 
ErbB  v-erb-b2 erythroblastic leukemia viral oncogene 
homolog 
Erk    extracellular-signal regulated kinase 
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ERT    tamoxifen-inducible estrogen receptor 
et al.     et alii (lat. and others) 
EtOH     ethanol 
FCS    fetal calf serum 
FDA     Federal Drug Agency 
Fig.     figure 
FITC     fluorescin isothiocyanate 
flox    floxed 
Fn1    fibronectin 1 
FOP     SuperFOPFlash expression plasmid 
FOXO     Forkhead (FKHR) family of transcription factors 
Fu     Fused 
Fzd    frizzled  
g     gramm 
g    g-force 
GAPDH    glyceraldehyde 3-phosphate dehydrogenase 
gDNA    genomic DNA 
GFP     green fluorescent protein 
Gli     Glioma-associated oncogene family member 
GliR     Gli repressor form 
GmbH & Co KG  limited partnership with a limited liability company as 
general partner (german: Gesellschaft mit 
beschränkter Haftung Compagnie und 
Kommanditgesellschaft) 
GmbH  limited liability company (german: Gesellschaft mit 
beschränkter Haftung) 
GPCR    G-protein coupled receptor 
G-Phase   gap phase 
Gsk3    glycogen synthase kinase 3  
h     hour 
H2O2    hydrogen peroxyde 
HCl    hydrochloric acid 
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H&E     haematoxylen and eosin 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HEK-293   human embryonic kidney cells 293 
HGF     hepatocyte growth factor  
Hh     Hedgehog 
HNRNPA0   heterogeneous nuclear ribonucleoprotein A0 
Hprt     hypoxanthine phosphoribosyltransferase 1 
HRP     horse-raddish peroxidase 
HRPO    horse-raddish peroxidase 
Hsc70    heat-shock protein 70 
HSPGs   heparan sulfate proteoglycans  
i.e.     id est (lat. that is) 
Ig    immunoglobulin 
Igf2bp1  insulin-like growth factor 2 mRNA binding     protein 
1  
IHC     immunohistochemistry 
Ihh     Indian hedgehog 
Ihog     interference hedgehog 
i.m.     intramuscular 
Inc.     incorporated 
i.p.     intraperitoneal 
IP3    inositol 1,4,5-triphosphate  
Ivl     involucrin 
JNK    c-Jun N-terminal kinase  
k    kilo 
K1     keratin 1 
K10     keratin 10 
kb     kilobase 
KCl     potassium chloride 
KH2PO4    monopotassium phosphate 
KG limited Partnership (german: 
Kommanditgesellschaft) 
VII          Abbreviations 
137 
 
l     liter 
LacZ     β-Galactosidase 
LAR II    Luciferase Assay Reagent II 
LB     lysogeny broth 
Lef     lymphoid enhancer factor  
LiCl    lithium chloride 
log     logarithm 
LOH     loss-of -heterozygosity 
Lor     loricrin 
Lrp     LDL receptor-related protein 
Ltd.     limited 
m     meter 
m     milli 
m     murine  
m    slope 
M     molar 
Map    Mitogen-activated protein 
Mapk    Mitogen-activated protein kinase 
Map3k   Mitogen-activated protein kinase kinase kinase 
MB     medulloblastoma 
MEF     mouse embryonic fibroblast 
Mek    MAPK/ERK kinase 
MgCl2    magnesium dichloride 
MetOH    methanol 
min     minute 
mRNA   messenger ribonucleic acid 
MSCV    murine stem cell virus 
mTOR   mammalian target of rapamycin 
Myc    myelocytomatosis oncogene 
n     nano 
Na    sodium 
Na2HPO4    disodium hydrogen phosphate 
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NaCl     sodium chloride 
Nfat     nuclear factor associated with T cells 
Nf-κB     kappa light polypeptide gene enhancer in B cells 
NIH    National Institutes of Health 
NMSC    non-melanoma skin cancer 
n.s.     not significant 
N-terminal    aminoterminal 
OD     optical density 
O/N     overnight 
p     pico 
p     plasmid 
p    phospho      
PBS     Phosphate-buffered sodium chloride-solution  
PBST Phosphate-buffered sodium chloride-solution with 
Tween-20 
PCR     polymerase chain reaction 
PCP    planar cell polarity 
PDGF    platelet derived growth factor 
PDGFR   platelet derived growth factor receptor 
pH     lat. potentia hydrogenii 
PI     propidium iodide 
PI3K      phosphatidylinositol-4,5-bisphosphate 3-kinase   
PIP3    phosphatidylinositol-3,4,5-triphosphate  
Pk     prickle 
PKC    protein kinase C 
PLB     passive lysis buffer 
PLC    protein lipase C 
POD     peroxidase 
Porcn     palmitoyltransferase porcupine 
PS     penicillin/streptomycin 
PSMF    phenylmethanesulfonylfluoride 
Ptch     patched1 
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Ptch2     patched2 
Ptk7    protein tyrosine kinase 7  
Puro    puromycin 
Pygo     pygopus 
qRT-PCR    quantitative real-time PCR 
Raf 
Ras     rat sarcoma virus oncogene homolog 
RIPA buffer   radioimmunoprecipitation assay buffer 
Rlu    relative light units 
RMS     rhabdomyosarcoma 
RNA     ribonucleic acid 
RNase   ribonuclease 
Rock   Rho-associated coiled-coil containing protein kinase 
Ror    receptor tyrosine kinase-like orphan receptor  
rRNA     ribosomal RNA 
RT     room temperature 
RYK    receptor tyrosine kinase 
S6     ribosomal protein S6 
SAPK    stress-activated phospho-kinases 
SCC     squamous cell carcinoma 
SDS     sodium dodecyl sulfate 
Sdc-2    syndecan-2 
sec     second 
SEM     standard error of the mean 
Sfrp     secreted frizzled-related protein 
Shh     sonic hedgehog 
Sma    smooth muscle actin 
Smo     smoothened 
SmoM2  constitutively active W539L point mutation of the 
mouse smoothened homolog gene 
SN    supernatant 
SOC     super optimal broth with catabolite repression 
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SOS    son of sevenless 
SPF     specified pathogen-free 
S-Phase   synthesis phase 
St.    saint (german: Sankt) 
STAT    signal transducer and activator of transcription 
stauro    staurosporine  
Sufu    suppressor of fused homolog 
SYBR    Synergy Brands Inc. 
TAMs    tumor-associated macrophages 
Taq    thermos aquaticus 
TBE    Tris-boric acid-EDTA-solution 
Tbp    TATA box binding protein 
TBS    Tris-buffered sodium chloride-solution 
TBST Tris-buffered sodium chloride-solution containing 
Tween-20 
Tcf     T-cell factor 
TE    Tris/EDTA buffer 
TF     transcription factor 
TGF-β    Transforming growth factor beta 
Tgm1     transglutaminase 1 
TK     thymidine kinase 
Tle  transducin-like enhancer of split 
TOP     SuperTOPFlash expression plasmid 
TP53    tumor protein p53  
β-TrCP    beta-transducin repeat containing protein  
Tris     tris(hydroxymethyl)aminomethane 
TUNEL TdT-mediated dUTP-biotin nick end labeling 
U     unit 
USA     United States of America 
UV     ultraviolet 
V     Volt 
v     volume 
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Vangl     vang-like  
VEGF    vascular endothelial growth factor  
vs     versus 
W     Watt 
w     weight 
WD    WIF domain 
WHO     World Health Organization 
Wif1    Wnt inhibitory factor 1 
wk     week 
Wls    wntless 
Wnt     wingless-type MMTV integration site family 
WST-1   water soluble tetrazolium salt 1 
wt    wild-type 









This thesis would not have been possible without the support and aid of all 
the people which accompanied me on my way to complete this study. First of 
all I would like express my endless gratitude to my supervisor Prof. Dr. Heidi 
Hahn. Thank you for your support, continuous mentoring, numerous 
discussions and proofreading of this thesis. Thank you for giving me the 
opportunity to work on this exciting project. 
Many thanks also to the members of my thesis committee Prof. Dr. Matthias 
Dobbelstein and Prof. Dr. Tobias Pukrop for your helpful input and numerous 
ideas.  
Special thanks go to Dr. Kai Dittmann for all your support and advice in all 
the experiment requiring flow cytometry and for the joyful small talks that 
made my visits in the department of immunology a pleasant stay. 
A big thank to Prof Dr. Walter Schulz-Schaeffer for the interpretation of all my 
antibody stainings. 
I also would like to thank Prof. Dr. Michael Schön for his support and for 
providing human tissue samples. 
Special thanks also go to the animal care takers, especially Susann Peter 
and Jennifer Flemming for the excellent animal care and being a memory aid 
when my animals desperately needed to “retire”. 
Countless thanks go to the people of the lab I loved to work with, many of 
them became more than colleagues. In particular, I would like to thank Dr. 
Frauke Nitzki for your patients and guidance in the very beginning of this 
project and Benedikt Linder for always having an open ear, for all the 
discussions, BBQs and hours in the gym to forget the lab for a while. 
Moreover, I would like to thank Anke Frommhold, Ina Heß and Eva Stetter for 
your great support and backup during all the time. You rock! Many Thanks 
also to all the other current and former lab members, Dr. Anja Uhmann, 
Dr.Simone König, Dr. Diana Rettberg, Dr. Penelope Pelczar, Rosalie 
Ridzewski, Julia Dräger, Joana Pyczek, Nicole Cuvelier and Tobias Goldak 
VIII  Acknowledgements 
143 
for your support and making this a wonderful experience. It was great to work 
with all of you. 
I would also like to thank Prof. Peter Burfeindt and Dr. Silke Kaulfuß for 
adopting me for lunch and all the funny moments and discussion during all 
the years. 
Especially, I would like to thank my friends and my parents Ingrid and 
Herbert, to whom I would like to dedicate this thesis, for their endless support 
and encouragement during my studies and my thesis. I would not have made 
it without you. Thank you with all my heart! 
Finally, I would like to express special thanks to Pia who supported me 
throughout the critical phase. Thank you for your patience and your 
warmness. 
IX  Curriculum vitae 
144 
 
IX Curriculum vitae 
 
Personal information  
Name: Marco Becker  
Date of Birth: 23.07.1985  
Place of Birth: Gelsenkirchen, Germany  
Citizenship: German  
 
01/2012-09/2015  Research assistant (Ph. D. candidate),  
Georg-August-University Göttingen  
University Medical Center Göttingen; Institute of Human 
Genetics, Tumor Genetics group  
Within the Göttingen Graduate School for 
Neurosciences, Biophysics and Molecular Biosciences 
(GGNB) and the doctoral program Molecular biology of 
cells that is part of GAUSS  
(Georg-August University School of Science)  
Thesis title: “Wif1 Inhibits the Growth of Basal Cell 
Carcinoma”  
 
10/2009-01/2012  M.Sc., Georg-August-University Göttingen  
Within the master program “Developmental, Neural and 
Behavioral Biology” with focus on “Cell and 
Developmental Biology”. 
Thesis title: “The Role of Wif1 in Basal Cell Carcinoma”  
 
10/2006-07/2009  B.Sc., Georg-August-University Göttingen  
Within the bachelor program “Biology” with focus on 
“Molecular Biosciences”.  
Thesis title: “Aspects of the Putative Pluripotency Gene 
Stra8”  
 
07/2005   Abitur, Gymnasium-Petrinum Dorsten.  
 
Publications  
Frauke Nitzki, Marco Becker , Anke Frommhold, Walter Schulz-Schaeffer 
and Heidi Hahn (2012) “Patched Knockout Mouse Models of Basal Cell 
Carcinoma”; Journal of Skin Cancer, Volume 2012 (2012), Article ID 907543 
